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INTRODUCTION 
 
            An ideal dosage form regimen in drug therapy of my disease is the one which 
immediately attains the desired therapeutic concentrations of drug in plasma and maintain it 
constant for entire duration of treatment. 
          
            The drug  may  administered  by  variety  of  routes of  dosage  forms. The  oral  route of 
drug  administration  is  most popular and  has  been  successfully used  for  conventional 
delivery  of  drugs.  It  offers the  advantage  of  convenience, ease of  administration,  greater 
flexibility  in  dosage  forms  design, ease  of  production  and  low  cost.  Hence  it  is  adopted 
wherever  possible. It is propable  that  at  least  90%  of  all  drug  is  used  to  produce systemic  
effects  are  administered  by  oral  route. 
         
            The  dosage  forms  available  for  oral  administration  are  liquid  like solution, 
suspension,  emulsion  and  solids  like  powders,  tablets  and  capsules. The  physical  state  of 
most  of  the  drug  being  solid  which  are administered  in  solid  dosage  forms. 
 
Among   the  drugs  that  are  administered  orally,  solid  dosage form  represents  the 
Predefined  class of  product.  They  are  versatile,  flexible  in dosage  strength  relatively stable,  
present  lesser problem  in  formulation  and packing  and  it  is  convenient  to manufacture , 
store,  handle  and  use.  Solid dosage  form  provides  best  protection  to the  drug  against  
temperature,  humidity,  oxygen,  light  and  stress  during  transportation of  two  solid  dosage  
forms  that  is  tablets  and  capsules.  The  tablets  are  in wide  use.1,2 
 
1.1 TABLETS:3,4  
           Tablets  may  be  defined  as solid  pharmaceutical  dosage  forms containing  drug 
substance  with  or  without  suitable  diluents  and  prepared  by either  direct compression  or  
moulding  methods. 
Advantages of tablets:5 
 Ease of accurate dosing and low content variability 
 Good physical and chemical stability 
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 Competitive unit production costs 
 High level of patient acceptability 
 High convenience 
 Easy to package and ship 
 Simple to identify 
 Convenience of self administration. 
 
Disadvantages of tablets:5 
  Irritant effects on the gastro intestinal mucosa by some solids (e.g. aspirin) 
  Possibility of bioavailability problems resulting from slow disintegration and dissolution 
  Difficulty in swallowing in some patients; pediatrics and geriatrics 
  Some drugs resist compression into tablets 
  In emergency cases, intravenous or intramuscular injections are more effective. 
 
  Types of tablets:6 
         
          A) Oral Tablets for Ingestion 
                  
                 Standard compressed tablets 
                  Multiple compressed tablets 
                                   a. Layered tablets 
                                   b. Compression coated tablets 
                                   c. Inlay tablets 
                  Modified release tablets 
                  Delayed action tablets 
                  Targeted tablets 
                                  a. Floating tablets 
                                  b. Colon targeted tablets 
                  Chewable tablets 
          B) Tablets Used In the Oral Cavity 
                  
                  Buccal tablets 
                  Sublingual tablets 
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                  Troches and lozenges 
                  Dental cones 
         C) Tablets Administered By Other Routes 
                 
                 Implantation tablets 
                 Vaginal tablets 
         D) Tablets Used To Prepare Solution 
                  
                  .     Effervescent tablets 
                  .     Dispersible tablets 
                  .     Hypodermic tablets 
                  .     Tablet triturates      
 
1.2 METHODS OF MANUFACTURING:3 
               Tablets are manufactured by either dry/ wet granulation or direct compression method. 
Wet granulation: 
               It is the process in which a liquid is added to a powder in a vessel equipped with any of  
agitation that will provide agglomeration or granules. These granules are then compressed to 
form tablets. 
Dry granulation: 
               In this technique no use of liquids. The process involves the formulation of slug. Then 
the slugs are mixed and screened to produce granules. These granules are then compressed to 
form tablets. 
Direct compression: 
               The term direct compression is used to define the process by which the tablets are 
compressed directly, forms powder blends of active ingredients and suitable excipients [fillers, 
disintegrants and lubricants]  which will flow uniformly in the die cavity and forms a firm 
compact. 
Advantages of  Direct compression: 
 More economical. 
 Less processing time and process validation. 
 No need of moisture, heat and high compaction pressure. 
 Optimization of tablet disintegration eg.starch more effective. 
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1.3  SUSTAINED RELEASE CONCEPT: 
 The goals of sustained drug delivery are to conserve and maintain effective drug 
concentration, eliminate night time dosage, improve compliance and decrease side   
effects thus optimizing drug therapy.(7)  Sustained release dosage forms provide a dosing 
of the drug from the product by supplying an initial amount (or) loading dose, perhaps 
one-half of the total dose release, followed by a gradual and uniform release of the 
remainder drug over the desired time period. 
 Sustained release dosage form are designed to achieve a prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after administration of 
a single dose.(8)  
Advantages of Sustained Release Drug Delivery:(9) 
 Reduced frequency of drug. 
 Improved patient compliance 
 Reduced blood level oscillation characteristic of multiple dosing of conventional dosage 
forms. 
 Reduced amount of drug administration. 
 Maximizing availability with a minimum dose. 
 Safety margin of high potency drugs can be increased. 
 Incidence of both local and systemic adverse effects can be reduced. 
 Increased reliability of therapy. 
Disadvantages of Sustained Release Drug Delivery: 
 Administration of sustained release medication does not prompt termination of therapy. 
 The physician has less flexibility in adjusting dosage regimen. 
 Sustained release forms are designed for the normal population. 
 Economic factors must also be assessed. 
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Pharmacokinetic Model of Sustained Release Dosage Form: 
 
          
                                                                          Ka                                             Ke 
       
 
 
Tm 
                 Kr 
           For optimizing sustained release dosage form designs, some specific parameters must be 
taken. These are: 
 The loading or immediately available portion of the dose (Di). 
 The maintenance or slowly available portion of the dose (Dm). 
 The time at which release of maintenance dose begins (Tm). 
 Specific rate of release (Kr) of the maintenance dose. 
 
1.4  BILAYER TABLETS: 
           Bilayer tablets concept has long been utilized to develop extended release and immediate 
formulation for a single drug or combination of drugs [10]. Bi-layer extended release tablet 
generally has a fast releasing layer and control releasing layer to sustain the drug release. The 
pharmacokinetic advantage relies on the criterion that, drug release from the fast releasing layer 
leads to a sudden rise in the blood concentration and the blood level is maintained at steady state 
by the sustained release layer [11]. The present study is planned to evaluate the suitability of 
different polymers for bilayer matrix tablets. Formulations were evaluated with respect to 
various parameters like weight variation, hardness, friability, thickness, content uniformity and 
in -vitro dissolution rate. 
           The immediate release layer and extended release layer were prepared by wet granulation 
technique. Hydroxypropylmethyl cellulose (HPMC 15 cps, HPMC 100 cps and Methocel 
K4MCR) was used as release rate retardant. Hydroxypropylmethyl cellulose (HPMC) is used 
frequently as a rate-controlling polymer in matrix tablets [12]. HPMC offers the advantages of 
Peripheral            
͞TISSUE͟ 
             Dosage form 
Maitenance    Loading    
    dose               dose 
     Dm                  Di       
x
Central  ͞Blood͟             
Vc 
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being non-toxic and relatively inexpensive; it can be compressed directly into matrices and is 
available in different chemical substitution and hydration rates and viscosity grades [13-14]. 
   
 
 
Fig.1.Bilayered tablets (same drug with different release pattern-homogenous) 
 
NEED OF BILAYER TABLETS: 15 ,16 ,17 
 
1. For the administration of fixed dose combinations of different APIs, prolong the drug 
product life cycle, buccal/mucoadhesive deliver systems; fabricate novel drug delivery 
systems such as chewing device and floating tablets for gastro-retentive drug delivery. 
2. Controlling the delivery rate of either single or two different active pharmaceutical 
ingredient(s). 
3. To modify the total surface area available for API layer either by  sandwiching with one 
or two in active layers in order to achieve swellable/erodible barriers for modified 
release. 
4. To separate incompatible Active pharmaceutical ingredient (APIs) from each other, to 
control the release of API from one layer by utilizing the functional property of the other 
layer (such as, osmotic property). 
IDEAL CHARACTERSTICS OF BILAYER TABLETS: 
1.  A bi-layer tablet should have elegant product identity while free of defects like chips, 
cracks, discoloration and contamination. 
2.  It should have sufficient strength to with stand mechanical shock during its production 
packaging, shipping and dispensing. 
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3.  It should have the chemical and physical stability to maintain its physical attributes over 
time. The bi-layer tablet must be able to release the medicinal agents in a predictable and 
reproducible manner. 
4.  It must have a chemical stability shelf-life, so as not to follow alteration of the medicinal 
agents. 
 
PREPARATION OF BILAYER TABLETS:18,19,20,21 
 
            Bilayer tablets to produce adequate tablet formulation, certain requirements such as 
sufficient mechanical strength desired drug release profile must be met. At times, this may be 
difficult task for formulator to achieve these conditions especially in bilayer tablet formulation 
where double compression technique is involved, because of poor flow and compatibility 
characteristic of the drug which will result in capping and/or lamination. The compaction of a 
material involves both the compressibility and consolidation. 
 
Compression: 
           It is defined as reduction in bulk volume by eliminating voids and bringing particles into 
closer contacts. 
Consolidation:  
           It is the property of the material in which there is increased mechanical strength due to 
interparticulate interaction (bonding). The compression force on first  layer  was found to be 
major factor influencing tablet delamination. 
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                                    Fig 2: Preparation of bilayer tablet Compaction. 
 
 
VARIOUS TECHNIQUES FOR BILAYER TABLET: 
 
OROS® PUSH PULL TECHNOLOGY:22,23,24 
          This system consist of mainly two or three layer among which the one or more layer are 
essential of the drug and other layer are consist of push layer. The drug layer mainly consists of 
drug along with two or more different agents. So this drug layer comprises of drug which is in 
poorly soluble form. There is further addition of suspending agent and osmotic agent. A semi 
permeable membrane surrounds the tablet core. 
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      Fig. 3: Bilayer and trilayer OROS push pull technology 
   
EN SO TROL TECHNOLOGY: 
            Solubility enhancement of an order of magnitude or to create optimized  dosage form 
Shire laboratory use an integrated approach to drug delivery focusing on identification and 
incorporation of the identified enhancer into controlled release technologies. 
 
                             
                                        Fig: 4: EN SO TROL Technology 
               
DUROS TECHNOLOGY: 
            The system consists from an outer cylindrical titanium alloy reservoir. This  reservoir has 
high impact strength and protects the drug molecules from enzymes. The DUROS technology is 
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the miniature drug dispensing system that opposes like a miniature syringe and reglious minute 
quantity of  concentrated   form in continues and consistent from over months or year. 
            
                        
 
                                              Fig. 5: DUROS Technology 
ELAN DRUG TECHNOLOGIES DUAL RELEASE DRUG DELIVERY SYSTEM: 
            (DUREDAS Technology) is a bilayer tablet which can provide immediate or sustained  
release of two drugs or different release rates of the  same drug in one dosage form. The  
tabletting process can provide an immediate release granulate and a modified-release  
hydrophilic matrix complex as separate layers within the one tablet. The modified-release  
properties of the dosage form  are provided by a combination of hydrophilic polymers. 
 
BENEFITS OFFERED BY DUREDAS TM TECHNOLOGY INCLUDE: 
 Bilayer  tabletting  technology.  
 Tailored release rate of two drug components. 
 Capability of two different CR formulations combined. 
 Capability  for  immediate release  and  modified  release  components  in  one tablet.                  
L  OROS TM TECHNOLOGY22,23,24:         
           This system used for the solubility issue Alza developed the L-OROS  system where a 
lipid soft gel product containing drug in a dissolved state is  initially manufactured   and   then 
coated with a barrier membrane, than osmotic  push layer and than a semi permeable membrane, 
drilled with an exit orifice. 
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                                   Fig.6: L–OROS TM Technology 
                  
SMALL-SCALE BI-LAYER  
 5 KN First Layer Tamping Force.  
 40 KN Precompression Force.  
 80 KN Main Compression Force.  
 Single-Layer Conversion Capability  
Advantages of the bi-layer tablet dosage forms are25: 
1. They are unit dosage form and offer the greatest capabilities of all oral dosage form      
for thegreatest dose precision and the least content variability. 
2. Cost is lower compared to all other oral dosage form.  
3. Lighter and compact. 
4. Easiest and cheapest to package and strip. 
5. Easy to swallowing with least tendency for hang-up. 
6. Objectionable odour and bitter taste can be masked by coating technique.  
7. Suitable for large scale production. 
8. Greatest chemical and microbial stability over all oral dosage form.  
9. Product identification is easy and rapid requiring no additional steps when employing 
an embossed and/or monogrammed punch face.  
Disadvantages of Bi-Layer Tablet Dosage Forms are25:  
1. Difficult to swallow in case of children and unconscious patients.  
2. Some drugs resist compression into dense compacts, owing to amorphous nature, low  
density character. 
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3. Drugs with poor wetting, slow dissolution properties, optimum  absorption  high in 
GIT  may be difficult to formulate or manufacture as a tablet that will still provide 
adequate or full drug bioavailability. 
4. Bitter tasting drugs, drugs with an objectionable odor or drugs that are sensitive to 
oxygen may require encapsulation or coating.  
 
CHALLENGES IN BILAYER TABLETS  MANUFACTURING26: 
 
           Conceptually, bilayer tablets can be seen as two single-layer tablets compressed into one. 
In Practice, there are some manufacturing challenges. 
Delamination: 
 
          Tablet falls apart when the two halves of the tablet do not  bond completely. The two 
granulations should adhere when compressed. 
Cross-contamination:  
When the granulation of the first layer intermingles with the granulation of the second 
layer or vice versa, cross-contamination occurs. It may conquer the very purpose of the bilayer 
tablet. Proper dust collection goes a long way toward preventing cross contamination. 
 
Production yields:                
           To prevent cross contamination, dust collection is required which leads to losses. Thus, 
bilayer tablets have lower yields than single-layer tablets. 
 
Cost: 
           Bilayer tableting is more expensive than singlelayer tableting for several reasons. First, 
the tablet press costs more. Second, the press generally runs more slowly in bilayer mode. Third, 
development oftwo compatible granulations is must, which means more time spent on 
formulation development, analysis and validation.  
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2.   LITERATURE REVIEW 
Swati Aggarwal. et al.,27  reviewed on the oral drug delivery system, types of tablets, 
and challenges in bilayer tablet manufacturing, various tablet presses used, quality and GMP 
requirements for their production and recent developments in the field of bilayer technology. 
Oral drug delivery remains the preferred route of drug delivery. Novel technologies with 
improved performance, patient compliance and enhanced quality have emerged in the recent 
past. Multilayer tableting is getting increasing attention from a variety of industries for a variety 
of reasons: patent extension, therapeutic, marketing to name a few. To reduce capital investment, 
quite often existing but modified tablet presses are used to develop and produce such tablets. 
While general tablet manufacturing principles remain the same, there is much more to consider 
because making multi-layer tablets involves multiple-often incompatible products, additional 
equipment and many formulation and operation challenges. 
  
Gattani SG. et al.,28 developed a bilayer tablet of metoclopramide hydrochloride (MTH) 
and diclofenac sodium (DS) in separate layers to avoid incompatibility and thus to maximize the 
efficacy of both drugs in combination for the effective treatment of migraine headaches. MTH 
and DS were formulated as immediate and sustained release layers respectively. In-vitro 
dissolution kinetic studies of an optimized formulation of DS in both sustained release layer and 
bilayer tablet forms show good linearity of regression coefficient 0.9773 (first order equation). 
An optimized immediate release layer of MTH and a sustained release layer of DS might be 
suitable for the treatment of migraine by sequential release of the two drugs in a bilayer tablet. 
 
Chithirra Anbalaghan. et al.,29 prepared frusemide bilayer tablets. It consists of loading 
layer and controlled release layer. Crospovidone and sodium dodecyl sulphate were used for 
loading dose. Eudragit RL100 was used for controlled release layer. Tablets were evaluated for 
physicochemical properties such as hardness, friability, thickness, weight variation and drug 
content uniformity. FTIR studies revealed that there was no interaction between drug and 
polymers used in the study. In-vitro dissolution studies were carried out in USP type II paddle 
type apparatus. An Optimized formulation releases the drug up to 24 hours and it also fulfilled 
requirements such as easy to fabricate, inexpensive and high patient compliance. 
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Hosna Banu. et al.,30 designed acetaminophen extended release bi layer tablets 
containing immediate release layer and extended release layer. Tablets were prepared by wet 
granulation technique using different grades of hydroxypropylmethyl cellulose as release rate 
retardant. In- vitro release rate decreased with increase of polymer loading and viscosity. Drug 
release was analyzed using zero-order, first order, Higuchi and Korsmeyer-Peppas equations to 
explore and explain the mechanism of drug release from the bi layer matrix tablets. 
Mathematical analysis of the release kinetics indicated that release from the matrix tablets 
followed Fickian diffusion. So the bi-layer tablets could be a potential dosage form for delivering 
acetaminophen. 
                                                                     
Jain Jitendra. et al.,31 developed a bilayer-floating tablet (BFT) for Indomethacin using 
direct compression technology were punched using optimized solid dispersion, HPMC K4M, 
Avicel PH-112, ac-di-sol, magnesium stearate and aerosil in fast release layer and optimized 
floating layer as sustained release layer. Tablets were evaluated for physico-Chemical properties 
such as Hardness, Friability, Thickness, weight Variation and drug content uniformity. FT-IR 
studies revealed that there was no interaction between the drug and polymers used in the study. 
In- Vitro dissolution studies were carried out in a USP type II Paddle type apparatus. The 
optimized formulation showed no significant changes on stability studies when storing at 4º c, 
40º c, /75%RH, 60ºc /80% RH for 3 months. Optimized formulation release the drug up to 24hrs 
and fulfilled many requirements such as easy to fabricate, cost effective and high patient 
compliance. 
 
 
Reddi Prashanth. et al.,32 worked on  bilayer tablets containing Losartan Potassium  for 
immediate release using sodium starch glycolate as super disintegrant and Metoprolol succinate 
for extended release using Carbopol 71G, Hydroxy Propyl Methyl Cellulose (HPMC K100M), 
Xanthan gum and poly ethylene oxide as hydrophilic polymers and Kollidone as binder. The 
immediate layer was prepared by direct compression and extended release layer by wet 
granulation method. The tablets were evaluated for physiochemical properties. All the values 
were found to be satisfactory and were within limits with low standard deviation. In- 
vitro release studies were carried out using USP type II paddle apparatus in phosphate buffer (pH 
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6.8) for 12 h as dissolution medium. The best formulation was subjected accelerated stability 
studies and the formulation retained its physic chemical characteristics even after stressed . 
Antony Loebe. et al.,33  was designed to evaluate the short-term efficacy and safety of 
once-daily lurasidone (80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of 
schizophrenia. 
 
Crewe, Cheshire. et al.,34 sugessted Lurasidone is a novel benzoisothiazol antipsychotic 
that has recently been approved for the treatment   of schizophrenia in the U.S. Like many other 
second-generation antipsychotics, it has a high affinity fordopamine D(2) and serotonin 5-
HT(2A) receptors as well as a high affinity for 5-HT(7) receptors. It has negligible affinity for 
α(1) adrenoceptors, histamine H(1) receptors or muscarinic acetylcholine M(1) receptors. It has 
demonstrated efficacy in short-term trials versus placebo. The incidence of extrapyramidal 
symptoms (excluding akathisia/restlessness) was greater with lurasidone (14.7%) than placebo 
(5.1%). Akathisia and somnolence were dose-related adverse events. Lurasidone appears to have 
relatively little effect on weight, plasma glucose or lipids to date. No evidence of QTc 
prolongation was seen and orthostatic hypotension was uncommon. Raisedprolactin levels in 
short-term studies were dose-dependent, greater in females and occurred overall in 3.7 and 0.7% 
of lurasidone and placebo recipients, respectively. 
 
Nirav K. Joshi.et al.,35 developed and validated for the estimation of Lurasidone 
Hydrochloride in the Pharmaceutical dosage form. UV Spectrophotometric method was a simple 
one by estimation of Drug at 230 nm over the concentration range 10-50 ìg/ml for Lurasidone. 
The % recovery of the drug was found to be 98.5% – 100.16 %. Linearity was obtained 0.996 in 
the concentration range of 10-50 ìg/ml for Lurasidone. LOQ and LOD were found to be 8.43 and 
2.81 μg/ml respectively at 230nm for Lurasidone Hydrochloride. Assay of The Lurasidone 
Hydrochloride in Pharmaceutical Dosage Form was found to be 99.3 ± 1.44 %. Methods were 
validated according to ICH guidelines and can be used for analysis of dosage form. 
 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                                                              Page | 16  
 
Kirson NY. et al.,36  evaluated the effect of study designed on the comparative 
effectiveness of antipsychotic formulations. The optimal use of different antipsychotic 
formulations in a general clinical setting depends on better understanding of the underlying 
reasons for differences in effectiveness across research designs. While long-acting (depot) 
antipsychotic medications are often recommended to address adherence problems, evidence on 
the comparative effectiveness of depot versus oral antipsychotics is inconsistent. 
 
Herbert Y. Meltzer. et al.,37  designed to evaluate the short-term efficacy and safety of 
lurasidone in the treatment of acute schizophrenia. Lurasidone is a recently approved 
antipsychotic drug for schizophrenia, with daily doses up to 80 mg. Doses above that level were 
associated with increased levels of akathisia in this 6-week study. At recommended doses, 
lurasidone is efficacious for both positive and negative symptoms with no effect on metabolic 
parameters. Olanzapine was associated with greater significant improvement on some measures 
but also had increased metabolic effects. 
 
Jonathan M Meyer. et al.,38  described the development of lurasidone, including its 
receptor binding affinities, pharmacokinetics, CNS activity in rodent models and results of early 
clinical efficacy and safety studies in humans.  Lurasidone has a high affinity for dopamine 
D2 and serotonin 5-HT2A receptors as well as for receptors implicated in enhancement of 
cognitive function (e.g., 5-HT7, 5-HT1A, α2c). Lurasidone has no affinity for muscarinic M1 and 
histamine H1 receptors and minimal affinity for α1 adrenoceptors, dopamine D1 and D3 receptors, 
serotonin 5-HT2C receptors and α2A adrenoceptors. Phase II efficacy data indicate that lurasidone 
doses from 40 to 120 mg/day are effective in the treatment of schizophrenia, with positive 
symptom reduction exceeding that for negative symptoms, as seen with other antipsychotics. 
Preclinical data indicate that lurasidone reverses MK-801 induced learning and memory 
impairment in rodents, and active comparator data from a Phase Ib study of lurasidone 120 
mg/day versus ziprasidone 160 mg/day also found a signal for effects on cognition. Phase II 
studies suggest that lurasidone has no significant QTc prolongation and a benign metabolic 
profile. 
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New York University School of Medicine. et al.,39  worked for the treatment of acute 
schizophrenia in adults, and asenapine is also approved for the maintenance treatment 
of schizophrenia and as a monotherapy or as an adjunct to lithium or valproate for the treatment 
of bipolar manic or mixed episodes. The expectation is that these new agents will be less 
problematic regarding treatment-emergent weight gain and metabolic disturbances, which 
unfortunately can occur with several other second-generation antipsychotics. Asenapine is a 
sublingual preparation, in contrast to iloperidone and lurasidone, which are swallowed. 
Iloperidone and asenapine are dosed twice daily, in contrast to lurasidone, which is dosed once 
daily with food. Both asenapine and lurasidone can be initiated at a dose that is possibly 
therapeutic, but iloperidone requires 4 days of titration to reach its recommended target dose 
range. Although both asenapine and lurasidone can be associated with dose-related treatment-
emergent akathisia, iloperidone is essentially free of extrapyramidal adverse effects 
or akathisia throughout its recommended dose range. Sedation and/or somnolence have been 
reported with each medication. They are the most common adverse events associated with 
asenapine treatment, and are clearly dose-related for lurasidone. In contrast, no therapeutic dose 
response for iloperidone, asenapine, or lurasidone is clearly evident from short-term clinical 
trials. Longer-term and naturalistic studies will be helpful in evaluating these agents and their 
role in the psychiatric armamentarium. 
 
Henry A. Nasrallah. et al.,40  evaluated the efficacy, safety, and tolerability of treatment 
with the atypical antipsychotic lurasidone for patients with an acute exacerbation of 
schizophrenia. Patients were randomized to 6 weeks of double-blind treatment with lurasidone 
and placebo. Changes in Positive and Negative Syndrome Scale (PANSS) scores were evaluated 
using mixed-model repeated-measures (MMRM) analysis. Vital signs, laboratory parameters, 
extrapyramidal symptoms, and electrocardiogram were assessed. In this study, in which a large 
placebo response was observed, lurasidone was statistically superior to placebo in treating acute 
exacerbation of chronic schizophrenia. All lurasidone doses were generally well tolerated. 
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Amol Chaudhary. et al.,41 developed once-daily extended release tablet of Lamotrigine, 
were prepared by the wet granulation method. Lamotrigine using hydrophilic matrix material 
(Methocel K4M & Methocel K100LV) in combination with hydrophobic material (Eudragit L-
30D-55) were used, which can release the drug upto 24hrs in predetermined rate. Diluents used 
were lactose monohydrate and magnesium stearate as lubricant. The formulated tablets were also 
characterized by physical and chemical parameters. The granules showed satisfactory flow 
properties, compressibility, and drug content. The in-vitro release rate profile showed the higher 
concentration of 04-50ERT polymer in tablet, the combination of hydrophilic in core and 
hydrophobic in coating polymer showed less result than use of a single polymer. 
 
Ravisankar P. et al.,42 developed and validated for the determination of Lurasidone HCl 
in bulk and pharmaceutical formulations. Beer's law is obeyed in the concentration range of 2-
10μg/mL with good correlation coefficient (R2= 0.9995) and UV detection was done at 315 nm. 
The percentage recovery studies were performed and the percentage recovery was found to be of 
98.76 -99.84 %. The method was precise and the relative standard deviation was found to be 
0.98. Detection limit and Quantitation limit were found to be 0.253 μg/mL and 0.766 μg/mL 
respectively. The proposed method was successfully validated as per the ICH guidelines. This 
method can be used for the determination Lurasidone HCl in quality control laboratories without 
interference of excipients. 
 
Glen Oaks. et al.,43  designed  Lurasidone is a new second-generation (atypical) 
antipsychotic approved for the treatment ofschizophrenia in adults. The recommended dose is 
40-80 mg given once daily, with no titration needed. Lurasidone should be taken with food. The 
tolerability profile of lurasidone is noteworthy in terms of a good weight and metabolic profile 
and no cardiovascular adverse effects such as orthostatic hypotension or prolongation of the QTc 
interval. Lurasidone is associated with some somnolence,akathisia, nausea, and parkinsonism, 
especially early in treatment. It might be helpful for cognitive or depressive symptoms; early 
findings have shown some benefit in these areas, but additional studies are needed. Lurasidone 
may be particularly helpful for patients with schizophrenia who are overweight or 
have endocrine problems (diabetes, dyslipidemia) or comorbid cardiovascular conditions 
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M. Nischala. et al.,44 reviewed an introduction to bi-layer tablet technology, challenges 
in bi-layer tablet manufacturing, various tablet presses used, quality and GMP requirements for 
their production various techniques used for bi-layer tabletting and recent developments in the 
field of bi-layer technology. A controlled release formulation along with various features to 
provide successful drug delivery. Bi-layer tablets can be primary option to avoid chemical 
incompatibilities between APIs by physical separation and to enable the development of different 
drug release profiles. Bi-layer tablet is suitable for sequential release of two drugs in 
combination and also for sustained release of tablet in which one layer is for immediate release 
as loading dose and second layer is maintenance dose. So use of bi-layer tablets is a very 
different aspect for anti-hypertensive, diabetic, anti-inflammatory and analgesic drugs where 
combination therapy is often used. Several pharmaceutical companies are currently developing 
bi-layer tablets, for a variety of reasons: patent extension, therapeutic, marketing to name a few. 
General tablet manufacturing principles remain the same, there is much more to consider because 
making multi-layer tablets involves multiple often incompatible products, additional equipment 
and many formulation and operation challenges.  
  
 
Gurpreet Arora. et al.,45 developed an oral controlled release mucoadhesive matrix 
tablets of domperidone using natural mucoadhesive material myrrh oleo gum resin (MOGR). 
The tablets were formulated with the natural polymer in different concentration (5, 10, 15 and 20 
% w/w) employing direct compression technology. The tensile strength increases from 
0.973±0.09 to 1.687±0.11 MN/m2 and mucoadhesive strength from19.868 to 49.778 N with the 
increase in natural polymer concentration from 5 to 20 % (M1 to M4). Swelling index of natural 
polymer was testified towards proliferation by together increasing gum concentration and the 
time period. Accelerated stability studies demonstrate no significant change in the tensile 
strength, mucoadhesive strength and drug assay.  
 
Arun Kumar Das. et al.,46  developed a stable formulation of antipsychotics Quetiapine 
as an immediate-release tablet. Quetiapine has beneficial calming properties and successfully 
treats the symptoms of aggression, anxiety and hostility that can accompany acute exacerbations 
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of schizophrenia. The task of developing immediate release tablet is accomplished by using a 
suitable diluent and super-disintegrants. Faster disintegration of the tablet administrated orally 
minimizes absorption time and improves its bioavailability in less time. The optimized 
formulation is further selected and compared with the release profile of the innovator product 
and similarity factor was conducted. The result was found to be more than 50%.The optimized 
formulation was conducted for stability studies according to ICH guideline. There were 
insignificant changes during studies. Hence, the results suggest the feasibility of developing 
immediate release tablets consisting of Quetiapine, which has an excellent tolerability profile 
offering high patient acceptability that may promote patient adherence to medication and an 
improved quality of life. 
 
Morsu Ashok. et al.,47  developed controlled release formulation along with various 
features to provide a way of successful drug delivery system. Bilayer tablet is better than the 
traditionally used mouthwash,sprays,gels  So use of bilayer tablet is a very different aspect for 
anti-inflammatory and analgesic. Bi-layer tablet is suitable for sequential drugs in combination, 
separate two incompatible substances and also for sustained release tablet in which one layer is 
immediate release as initial dose and second layer is maintenance dose. Bilayer tablet is 
improved beneficial technology to overcome the shortcoming of the single layered tablet. 
Several pharmaceutical companies are currently developing bilayer tablet for a variety of reason: 
patent extension, therapeutic, marketing to name a few. To reduce capital investment quite often 
existing but modified tablet presses are used to develop such tablets. The present article provides 
an introduction to bilayer tablet technology, advantages and disadvantages, various techniques, 
quality and GMP requirements, characterization and evaluation of bilayer tablets. Bilayer tablet, 
various techniques, bilayer tablet presses, GMP requirements characterization and evaluation of 
bilayer tablet.                    
 
 
Motarwar S.S. et al.,48 developed to reduce capital investment quite often existing but 
modified tablet presses are used . Bilayer tablet is suitable for sequential release of two drugs in 
combination, separate two incompatible substances and also for sustained release tablet in which 
one layer is immediate release as initial dose and second layer is maintenance dose. Bilayer 
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tablet is improved beneficial technology to overcome short coming of single layer tablet. In the 
last decade interest in developing a combination of two or more active pharmaceutical ingredient 
in a single dosage form(bilayer tablet)has increased in the pharmaceutical industry, promoting 
patient convenience and compliance. several pharmaceutical companies are currently developing 
bilayer tablet for a variety of reason: patentextension, therapeutic, marketing to name a few.  
 
 
Arvind Mishra. et al.,49  developed bi-layer tablets, for a variety of reasons: patent 
extension, therapeutic, marketing to name a few. To reduce capital investment, quite often 
existing but modified tablet presses are used to develop and produce such tablets. Using a 
modified tablet press may therefore not be your best approach in producing a quality bi-layer 
tablet under GMP-conditions, especially when high production output is required. Bilayer tablet 
is new era for the successful development of controlled release formulation along with various 
features to provide a way of successful drug delivery system.  
 
Preeti Karwa. et al.,50  designed in bilayer tablet of Zolpidem Tartrate for biphasic 
release and in- vitro evaluation of the same. Bilayer tablets comprised two layers, i.e. immediate 
release and controlled release layer. The immediate release layer comprised croscarmellose 
sodium as a super disintegrant and the controlled release layer comprised HPMC K100M as the 
release retarding polymers. Direct compression method was used for formulation of the bilayer 
tablets. HPMC K100M extended the release of drug from the extended release layer for 6 hr. 
There were no changes observed in physicochemical properties and drug release pattern of 
tablets. Biphasic drug release pattern was successfully achieved through the formulation of 
bilayer tablets in this study. 
 
Jaldhara S Patel.et al.,51 developed controlled release formulation along with various 
features to provide a way of successful drug delivery system. Controlled release dosage forms 
have been extensively used to improve therapy with several important drugs. Use of bilayer 
tablet is a very different aspect for anti-inflammatory and analgesic. Bi-layer tablet is suitable for 
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sequential release of two drugs in combination, separate two incompatible substances and also 
for sustained release tablet in which one Layer is immediate release as initial dose and second 
layer is maintenance dose. Bilayer tablet is improved beneficial technology to overcome the 
shortcoming of the single layered tablet.  
 
Rohan D. Deshpande. et al.,52  developed to achieve controlled delivery of different 
drugs with pre-defined release profiles. A combination of two or more Active Pharmaceutical 
Ingredients (API) in a single dosage form (bilayer tablet) has increased in the pharmaceutical 
industry, promoting patient convenience and compliance. Bilayer tablets can be a primary option 
to avoid chemical incompatibilities between API by physical separation, and to enable the 
development of different drug release profiles (immediate release with extended release). The 
development and production of quality bi-layer tablets needs to be carried out on purpose-built 
tablet presses to overcome common bi-layer problems, such as layer-separation, insufficient 
hardness, inaccurate individual layer weight control, cross-contamination between the layers, 
reduced yield, etc. Using a modified tablet press may therefore not be your best approach to 
producing a quality bi-layer tablet under GMP-conditions. Especially when in addition high 
production output is required. 
 
Buchi N. Nalluri. et al.,53  formulated controlled release (CR) oral matrix tablet 
formulations of Carvedilol (CAR), an antihypertensive using cellulose ether polymer, Hydroxy 
Propyl Methyl Cellulose (HPMC K4M, HPMC K15M) of different viscosity grades as drug 
release retardants. The tablets were prepared by direct compression technique and evaluated for 
various physico-chemical/mechanical parameters. Based on the viscosity and gel formation 
during dissolution, HPMC K4M was selected as release retardant. Based on the dissolution data 
obtained with different fillers and keeping in view of the results from the pre-compression 
studies, and gel layer retaining with the matrix tablets, Avicel PH 105 was selected to carry out 
further formulation development. The formulation containing 25%w/w HPMC K4M as release 
retardant and Avicel PH 105 gave 96.59 ± 3.1% release at the end of 24h and fulfils regulatory 
requirement.  
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V.Hima Bindu. et al.,54 designed on controlled release formulation along with various 
features to provide successful drug delivery. Bi-layer tablets can be primary option to avoid 
chemical incompatibilities between APIs by physical separation and to enable the development 
of different drug release profiles. Bi-layer tablet is suitable for sequential release of two drugs in 
combination and also for sustained release of tablet in which one layer is for immediate release 
as loading dose and second layer is maintenance dose. 
 
 
Pruthvipathy R. Katikaneni. et al.,55 designed Pseudoephedrine hydrochloride 
sustained release tablets to prepare direct compression with ethylcellulose (EC). Initially, 
different viscosity grades of EC were studied. An increase in viscosity grade resulted in a 
marginal to moderate increase in the release rate. However, lower viscosity grades produced 
harder tablets. The highly compressible 10 cp grade was used to study the effect of drug loading, 
particle size, compression force, and magnesium stearate concentration on release properties. 
The rate of drug release decreased with a decrease in the drug concentration in the matrix. The 
square of the release rate is proportional to drug concentration in the matrix, indicating that the 
release of pseudoephedrine hydrochloride from EC matrices is primarily matrix-controlled. 
 
Shankar S. J.et al.,56 prepared Modified release matrix tablets of ciprofloxacin 
hydrochloride with different polymers. The powder mixture was compressed by direct 
compression method into tablets using rotary tablet compression machine equipped with 13mm 
tooling of convex surface. Prepared tablets were evaluated for uniformity of content, hardness, 
thickness, weight variation, friability, in-vitro dissolution studies and stability studies. The in-
vitro dissolution study was carried out using USP dissolution test apparatus (paddle type) at100 
rpm. The test was carried out at 37 ± 0.5 0 C in 900ml of the N/10 Hcl buffer as the medium for 
two hours, and pH 7.2 buffer from 2nd hour to 12th hour. The average weight of tablet was 
observed to be within limits. In-vitro dissolution study indicated that matrices containing 
Chitosan and Guar gum in the ratio 2:1 showed 93.6 % release after 12 hrs. Whereas for the 
matrices containing lactose in the percentage of 50 and 75 showed 96.15 % and 99.90 % release 
after 12 hrs respectively. The prepared matrix tablets have not undergone any change either in 
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physical appearance, content or in the dissolution pattern after storage at 45○ C & 75 % RH over 
a period of 6 months. 
Hamdy Abdelkader. et al.,57  developed Baclofen from matrix tablets prepared by a hot-
melt granulation process (wax tablets) and wet granulation process (E-RS100 and E-L100 
tablets). Statistically significant differences were found among the drug release profile from 
different classes of polymeric matrices. Higher polymeric content (40%) in the matrix decreased 
the release rate of drug because of increased tortuosity and decreased porosity. At lower 
polymeric level (20%), the rate and extent of drug release was elevated. The release kinetics was 
found to be governed by the type and content of the excipients (polymer or filler). The prepared 
tablets showed no significant change in drug release rate when stored at ambient room conditions 
for 6 months. 
 
Leslie Citrome. et al.,58 developed Lurasidone is a second-generation antipsychotic 
newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia. 
Similar to most other second-generation antipsychotics, lurasidone is a full antagonist at 
dopamine D2 and serotonin 5HT2A receptors. Efficacy within the dose range of 40–120 mg/d 
was established in four 6-week, randomized, controlled trials. The recommended starting dose is 
40 mg/d and the maximum recommended dose is 80 mg/d. Doses above 80 mg/d do not appear 
to confer added benefit and may be associated with a dose-related increase in certain adverse 
reactions such as somnolence and akathisia. Lurasidone is primarily metabolized in the liver 
through the CYP3A4 enzyme system, and coadministration with drugs that are strong inhibitors 
of CYP3A4 (such as ketoconazole) or strong inducers (such as rifampin) are contraindicated. 
Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in 
glucose, lipids, or the ECG QT interval.  
 
 
Mali Nikita. et al.,59 developed for the estimation of Lurasidone hydrochloride in bulk 
and pharmaceutical formulations. Lurasidone hydrochloride was estimated at 227 nm in UV-
spectroscopic method (Method A), 237 nm in first order derivative spectroscopy (Method B) and 
scanned at 225.0 - 235.0 nm in Area under Curve method (Method C). Linearity range was found 
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to be 5-30 μg/ml (Correlation coefficient r = 0.999in method A, r = 0.999 in method B and r = 
0.999 in method C) in all the three methods. These methods were tested and validated for various 
parameters according to ICH guidelines. The proposed Methods were successfully applied for 
the determination of Lurasidone hydrochloride in pharmaceutical formulation (Tablets). The 
results of recovery were found to be 99.44-101.28 % for method A, -100.33- -101.46% for 
Method B, and for Method C % Recovery was found to be 99.83-100.76% which was within 
limits. (98-102%). Limit of Detection and Limit of Quantification were 0.2044, 0.6196 for 
method A, 0.6350, 1.9245 for method B and 0.0831, 0.2521 for method C. The results 
demonstrated that the procedure is accurate, precise and reproducible (% relative standard 
deviation <2%), while being simple, cheap and less time consuming and can be suitably applied 
for the estimation of Lurasidone hydrochloride in tablet dosage forms.   
 
Muvvala S Sudhir. Et al.,60 designed spectrophotometric method of analysis for 
lurasidone in bulk form was developed and validated. The absorbance was found to increase 
linearly with increasing concentration of lurasidone, which is corroborated by the calculated 
correlation coefficient value (r2 = 0.999). The linear regression analysis data for the calibration 
plot showed good linear relationship with in the concentration range of 10 – 60 μg/ml. The limit 
of detection and limit of quantitation were found to be 1.25316 μg/ ml and 3.797468 μg /ml 
respectively. This method was tested and validated for various parameters according to ICH 
guidelines. The results demonstrated that the procedure is accurate, precise and reproducible 
(R.S.D. < 2 %). 
 
Xiao Huang. et al.,61 reviewed experimental observations of burst release in monolithic 
polymer controlled drug delivery systems, theories of the physical mechanisms causing burst, 
some of the unique ideas used to prevent burst, and the treatment of burst release in controlled 
release models. The fast release of drug in a burst stage is utilized in certain drug administration 
strategies, the negative effects brought about by burst can be pharmacologically dangerous and 
economically inefficient. Therefore a thorough understanding of the burst effect in controlled 
release systems is undoubtedly necessary.  
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Koichiro Tahara. et al.,62 designed sustained release (SR) from tablet matrices prepared 
with hydroxypropyl methylcellulose (HPMC) 2910 polymers were investigated to define the 
conditions for selection of appropriate polymers for SR formulation development. It is well 
known that the two important parameters for the release of drug from tablet matrices are the 
infiltration rate of medium into the matrix, for those drugs with reasonable aqueous solubility, 
and the erosion rate of the matrix system, for those drugs with poor aqueous solubility. In 
addition, the amount of drug loaded into the tablet also influences the release rate of the drug. 
The infiltration rate of medium into the matrix can be controlled by changes in the interspace 
volume of the matrix by the use of higher levels of materials such as lactose, which quickly rinse 
out of matrix system. The larger interspace volumes produced by the higher ratio result in more 
rapid release of the drug. The viscosity of HPMC polymers is related to the molecular weight 
and has a large influence on the erosion rate of matrix tablet. Use of a low viscous grade HPMC 
polymer is desirable for drugs that are poorly water soluble since the erosion rate of the tablet 
matrix is the controlling factor for drug release. The release rate of poorly soluble drug can be 
controlled by the rate of tablet erosion. The tablet erosion rate can also be adjusted by the choice 
of HPMC polymer viscosity or by mixing HPMC of different viscosity grades. 
 
Mohammad Usman.et  al.,63 developed Mefenamic acid 200 mg controlled release 
matrices  by direct compression and in- vitro drug dissolution studies were performed to find out 
the drug release rate and patterns. Methocel was used as rate controlling polymer. Also the effect 
of several co-excipients was investigated on the drug release rates during in-vitro dissolution 
studies. Polymer Methocel was used as a rate controlling polymer and was formulated with the 
drug at 4 different D: P ratios. Phosphate buffer pH 7.2 was used as dissolution medium using 
PharmaTest dissolution apparatus. Several kinetic models were applied to the dissolution profiles 
to determine the drug release kinetics. Dissolution equivalency evaluation was performed using 
f2 similarity factor.   
 
Mayank Bansal. et al.,64 formulated an immediate release tablet of Zaltoprofen for the 
treatment of pain and inflammation, by using superdisintgrant such as Croscarmellose sodium 
and different grades of microcrystalline cellulose. Immediate release tablets of Zaltoprofen were 
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prepared by direct compression method using superdisintgrant such as Croscarmellose sodium 
and different grades of microcrystalline cellulose in different ratios. Sodium starch glycolate was 
added to aid disintegration. Tablets were subjected to physicochemical characterization such as 
thickness, hardness, friability, weight uniformity, drug content, disintegration time, in-vitro drug 
release, and stability study. Tablets were found to be satisfactory when evaluated for thickness, 
hardness, friability, weight uniformity, drug content, disintegration time and in-vitro drug 
release. The tablet disintegration time was less than one minute for all the tablet formulations. 
The in-vitro drug release in optimized formulation was found to be 98.89 % in 45 min. The 
optimized formulation also showed satisfactory hardness (5.83±0.556 kg/cm2), friability 
(0.425%±0.0029), drug content (98.29%±0.0657), weight variation (270.21±0.2184 mg), 
disintegration time (25.02±0.0028seconds) and stability. 
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3. RESEARCH ENVISAGED 
 
3.1  AIM OF  WORK 
         In the present work Lurasidone have been developed as a Bilayer Tablet formulation which 
is designed to get the Immediate Release and controlled release for 24 hours. 
         Psychosis  is  an abnormal condition of mind that causes people to perceive or interpret 
things differently from those around them. 
         Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and 
dopamine activity) to improve cognition. It reduce the extra pyramidal side effects that are often 
associated with typical antipsychotics. It’s half life is 18 hrs . Because of short half life and need 
of quick onset of action, Bilayered  tablets  were  formulated.    
Bilayer Tablet consist of two layers are  
                    1. Immediate Release 
                    2. Sustained  Release 
         When this bilayer tablet swallowed first fast release layer will dissolve immediately and 
give the onset of action. The remaining sustained release layer gives the therapeutic activity 
slowly until 24th hours. 
Objective of  Lurasidone Tablet: 
 Lurasidone  bilayer  tablets  were  formulated  with  following  objectives 
 To get controlled release.  
 To get quick onset of action. 
 To get quick dissolution of drug. 
 To get more bioavailability. 
 To prevent  dose dumping. 
 To access patient compliance. 
 To get dual action. 
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SCHEME FOR MECHANISM OF BILAYER TABLET 
 
                       BILAYER TABLET 
                                                       ↓ 
                                                 Swallowed 
          Immediate Release Layer                              Sustained  Release Layer  
             (first 30 minutes)                                            (after 30 minutes)            
                                                         ↓ 
                                                Disintegration 
                                                         ↓ 
                                                  Dissolution 
                                                         ↓ 
                                                 Bioavailability 
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3.2 PLAN OF WORK 
The scheme of the proposed work is as follows, 
- Preformulation studies 
        Angle of  Repose 
        Bulk  Density 
        Tapped  Density 
        Hausner  Ratio 
        Carr’s  Index 
- FTIR Studies 
- Preparation  of  Lurasidone  Bilayer Tablet by Direct compression 
- Evaluation  of  Bilayer Tablet 
        Diameter 
        Hardness 
        Thickness 
        Friability 
        Invitro-Dissolution  Study       
- Stability studies 
- Investigation of drug release kinetics 
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4.  METHODOLOGY 
4.1   MATERIALS USED:     
S.NO MATERIALS SUPPLIERS 
1 Lurasidone Kekule Pharma Ltd,  Hyderabad. 
2 Crospovidone Shasun Chemicals, Pondicherry. 
3 Croscarmellose Shasun Chemicals, Pondicherry 
4 Hydroxy propyl methyl cellulose Vigro chem,  India. 
5 Sodium lauryl sulphate Global Remedies & Drug Pvt., Ltd, 
Hosur. 
6 Micro crystalline cellulose Himedia Labs, Mumbai. 
7 Magnesium stearate Siani Pharmaceticals, India 
8 Talc Udaipur Minerals, India 
9 Starch Udaipur Minerals, India 
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4.1.1  INSTRUMENTS USED: 
 
 
 
 
S.NO INSTRUMENTS     SUPPLIERS 
    1 Single pan electronic balance 
 
Shimadzu corporation, Japan 
    2 pH  meter 
 
Elico Pvt Ltd,  Chennai. 
    3 Dissolution  apparatus 
 
DISS 2000, Lab India, Chennai 
    4 Disintegration  tester 
 
Electolab,  Chennai 
    5 Vernier  calipers 
 
Mitutoyo corps,  Japan 
    6 Hardness  tester 
 
Monsanto,  India 
    7 Single  beam  UV-Visible  
Spectrophotometer 
 
Shimadzu corporation 1201, Japan 
    8 16  Station  Rotary  tablet  compression  
machine 
 
Cadmach,  India 
    9 FTIR  Spectrophotometer 
 
Perkin-Elmer,  Germany 
  10  Stability  chamber 
 
Osworld,  Mumbai 
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4.1.2  DRUG PROFILE 
LURASIDONE42,65 
General  Description: 
 
 
Chemical Name: 
         (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl piperazin-1-
ylmethyl]cyclohexylmethyl} hexahydro-4,7-methano-2H-isoindole-1, 3-dione  hydrochloride 
Molecular Formula: 
          C28H36N4O2S∙HCl 
Molecular Weight: 
          529.14  
Description: 
          Lurasidone hydrochloride appears as a white to light yellow crystalline powder and stable 
upto thirty six months.  sparingly soluble In chloroform and acetonitrile ; slightly soluble in 
ethanol; in water and acetone  very slightly soluble in water and acetone , insoluble in toluene 
and 0.1 N HCl.  
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Melting Point:  
          198–2050C 
Density: 
          1.273 g/cc 
Mechanism of action:65 
          Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and 
dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can 
improve negative symptoms of psychosis and reduce the extrapyramidal side effects that are 
often associated with typical antipsychotics. 
Pharmacokinetics:66 
          Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 
1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal 
concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. 
Bioavailability = 9-19%. 
Distribution: 
          Volume  of  distribution  of  Lurasidone  is  613L  and  99%  Lurasidone bound to serum 
proteins. 
Metabolism: 
          Lurasidone is metabolized in the liver via the enzyme CYP3A44.  This means that its 
plasma concentrations may be increased when combined with CYP3A4 inhibitors like 
ketoconazole or grape fruit juice, possibly leading to more side effects. 
 
 Excretion: Lurasidone  excrets mainly by feces (80%)  and by urine (9%) also 
Therapeutic  Uses:67 
          Treatment of  schizophrenia. 
          For  treating the cognitive and memory deficits. 
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Contraindication:68 
          Elderly patients with dementia-related psychosis. 
          Placebo-treated patients. 
           Pregnancy and Breast-feeding.                                                       
Dosage and Administration : 
           For adults with schizophrenia, the recommended initial dose is lurasidone 40 mg orally 
daily with food. Initial dose titration is not required. The maximum recommended daily dose is 
80 mg. In patients with moderate and severe renal impairment (creatinine clearance [CrCl], 10–
50 ml/minute) and for those with moderate and severe hepatic impairment (Child–Pugh class B 
and C), the lurasidone dose should not exceed 40 mg/day. No dosage adjustments are necessary 
in the geriatric population. 
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4.1.3   Excipients Profile:69,70 
1.  CROSPOVIDONE (Kollidon CL)      
Synonyms: 
          Crosslinked povidone;  E1202; Kollidon CL;  Kollidon CL-M; 
Polyplasdone XL;  PolyplasdoneXL-10;  polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-
pyrrolidinone homopolymer. 
 
Chemical Name : 
          1-Ethenyl-2-pyrrolidinone homopolymer. 
 
Functional Category: 
         Tablet disintegrant 
 
Description: 
         Crospovidone is a white to creamy-white, finely divided, freeflowing, practically tasteless, 
odorless or nearly odorless, hygroscopic powder. 
Typical Properties: 
Acidity/alkalinity      :     pH = 5.0–8.0 (1% w/v aqueous slurry) 
Density                     :     1.22 g/cm3 
Density (bulk)           :     0.35 g/cm3 
Density (tapped)       :     0.45 g/cm3 
Moisture content       :    Maximum moisture sorption is approximately 60%. 
Solubility                   :    Practically insoluble in water and most common organic solvents. 
Specific surface area :    1.0 m2/g 
Storage Conditions   :    Crospovidone is hygroscopic, it should be stored in an             
                                        airtight container in a cool, dry place. 
Safety: 
         Crospovidone is used in oral pharmaceutical formulations and is generally regarded as a 
nontoxic and nonirritant material. 
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Applications: 
         Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2–5% 
concentration in tablets prepared by directcompression.       
         Crospovidone can be used to enhance the solubility of poorly soluble drugs in co-
evaporation technique. 
2.  Croscarmellose sodium 
Synonyms: 
         4C-Di-Sol, cross linked carboxy methyl cellulose sodium, modified cellulose gum 
nymulzsx, primellose, solutab. 
Chemical Name: 
         Cellulose, carboxy methyl ether sodium salt, cross linked. 
Moleculaer  Weight: 
         90000-700000 
Functional Category: 
         Tablet and capsule disintegrants. 
Description: 
         Croscarmellose sodium occur odorless, white or grayish white powder. 
Melting Point: 
         It browns at approximately 227oC, chars at approximately 252oC. 
Stability and storage conditions: 
         Croscarmellose sodium is a stable though hygroscopic material. A model tablet formulation 
prepared by direct compression with Croscarmellose  sodium as a disintegrants, showed no 
significant difference in drug dissolution after storage at 30oC for 14 months. 
         It should be stored in well closed container in a cool and dry place. 
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Safety: 
         It is regarded as a essential non-toxic and non-irritant materials. 
Application: 
         Croscarmellose sodium is used in oral pharmaceutical formulation as a disintegrant for 
capsule, tablets and granules. In tablet formulation, Croscarmellose sodium is used in both direct 
compression and wet granulation process. Concentration of  up to 5%w/w of  Croscarmellose 
sodium is used as a tablet disintegrant although normally 2%w/w is used in tablets by direct 
compression. 
3.  Magnesium Stearate: 
Synonyms: 
         Stearic acid, Magnesium salt, Magnesium octadeconate. 
Functional Category: 
         Tablet and capsule lubricant. 
Description: 
         It is fine, white, precipitated or milled, impalpable powder of low bulk density, having a 
faint odor of  stearic acid and characteristic taste. 
Typical Properties: 
         Density(tapped)  :  0.286 g/cm3 
         Density(bulk)      :  0.159 g/cm3 
Solubility: 
         It is soluble in water, ethanol and ether, slightly soluble in warm benzene and warm 
ethanol. 
Melting  Point: 
         117-150oC 
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Stability and  Storage Conditions: 
         It should be stored in a well closed container in cool and dry place. It is a stable compound. 
Incompatibilities: 
         Incompatible with strong oxidizing agent, strong acids, alkalies and iron salts. It cannot be 
used in product containing aspirin, some vitamins and most alkaloid salts. 
Safety: 
         It is widely used in pharmaceutical formulation and is generally regarded as a non-toxic 
material. However oral consumption of large quantity may result in some laxative effect or 
mucosal irritation. 
Application: 
         It is widely used in cosmetics, food and pharmaceutical formulation. It is  used as lubricant 
in capsule and tablet  formulation  at 0.25-5% concentration. 
4. Talc: 
Synonyms: 
         Magsilomanthus, Magsil star, Purified chalk, Powderde talc. 
Chemical Name: 
         Talc. 
Functional Category: 
         Anticaking agent, Glidant, Diluent and Lubricant for  tablet and capsule. 
Typical Properties: 
         Hardness                   :   1-1.5 
         Specific Gravity       :   2.7-2.8     
         Acidity / Alkalinity  :   6.5-10 
         Hygroscopic             :  Absorbs more amount of water at 25oC up to 90%    
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Solubility: 
         Insoluble in dilute acids and alkalis, organic solvents and water. 
 Stability and  Storage Conditions: 
         Talc is a stable material. It may be sterilized by exposure to ethylene oxide and heating and 
heating at 160oC. Talc should be stored in a well closed container in cool and dry place. 
Safety: 
         Talc is mainly used in tablet and capsule formulation. Inhalation fo talc caused irritation 
and severe respiratory distress in infants. The ovarian cancer is increased in women when using 
talc to its carcinogenic potential. 
Application: 
         Talc is widely used as a lubricant and diluents in oral solid dosage formulation. It is also 
used as dusting powder in topical preparation. It is also used as a lubricant in food products and 
cosmetics.     
5. Sodium  Lauryl  Sulphate:  
Synonyms: 
         Laurylsiran sondy , NaDS, Natrium laurylsulfuricum, SDS,SLS,Sodium lauril  sulfate,  
sodiumdodecyl  sulfate  
Chemical formula : 
         C12H25NaO4S 
Molecular weight: 
         Monoisotopic-288.137124653 
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Description: 
         Sodium lauryl sulfate is an anionic surfactant naturally derived from coconut and / or palm 
kernel oil.it usually consisting of a mixture of sodium alkyl sulfates , mainly the lauryl. 
Function Category: 
         Binder 
Application : 
         SLS lowers surface tension of aqueous solution and is used as fat emulsifier , wetting agent 
and detergent is also in cosmetics , pharmaceuticals and toothpasters. It is also used in creams 
and pasters to properly disperse the ingredients and as research tool in protein biochemistry.SLS 
also has some microbial activity.  
6. HYPROMELLOSE (HPMC K4M, K100M) 
Synonyms: 
         Benecel MHPC; E464; Hydroxypropyl methylcellulose; HPMC; Methocel; methylcellulose 
propylene glycol ether; methyl hydroxypropylcellulose; Metolose; Tylopur. 
Chemical Name: 
         Cellulose hydroxypropyl methyl ether. 
Functional Category: 
         Coating agent; film-former; rate-controlling polymer for sustained release; stabilizing 
agent; suspending agent; tablet binder; viscosity increasing agent. 
Description: 
         Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular 
powder. 
 
Typical Properties: 
Acidity/alkalinity             :  pH = 5.5–8.0 for a 1% w/w aqueous solution. 
Ash                                  :  1.5–3.0%, depending upon the grade and viscosity. 
Autoignition temperature:  360°C 
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Density (bulk)                  :  0.341 g/cm3 
Density (tapped)              :  0.557 g/cm3 
Density (true)                   : 1.326 g/cm3 
Melting point                   :  Browns at 190–200°C; chars at 225–230°C. 
Glass transition point       :  170–180°C. 
Moisture content              :  Hypromellose absorbs moisture from the atmosphere;                                         
                                             the amount of water absorbed depends upon the initial   
                                             moisture content and the temperature and                                             
                                             relativehumidity of the surrounding air. 
Solubility:                           
         Soluble in cold water, forming a viscous colloidal solution; practically insoluble in 
chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and dichloromethane, 
mixtures of methanol and dichloromethane, and mixtures of water and alcohol. Certain grades of 
hypromellose are soluble in aqueous acetone solutions, mixtures of dichloromethane and propan-
2-ol, and other organic solvents. 
 
Specific gravity:                  
         1.26 
Viscosity (dynamic):          
         A wide range of viscosity types are commercially available.  
 
Table 1: Typical viscosity values for 2% (w/v) aqueous solutions of HPMC. 
Viscosities measured at 20°C. 
 
Methocel product Nominal viscosity (mPas) 
HPMC K4M 4,000 
HPMC K100M 100,000 
 
Stability and Storage Conditions: 
         Hypromellose powder is a stable material, although it is hygroscopic after drying. Solutions 
are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions. Hypromellose 
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undergoes a reversible sol–gel transformation upon heating and cooling, respectively. The gel 
point is 50–90°C, depending upon the grade and concentration of material. 
Hypromellose powder should be stored in a well-closed container, in a cool, dry place. 
Safety: 
         Hypromellose is widely used as an excipient in oral and topical pharmaceutical 
formulations. It is also used extensively in cosmetics and food products. 
Applications: 
         Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical formulations. 
It  is also used as a suspending and thickening agent in topical formulations. It  is also used as an 
emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. It is used in the 
manufacture of capsules, as an adhesive in plastic bandages, and as a wetting agent for hard 
contact lenses. It is also widely used in cosmetics and food products. 
7. CELLULOSE, MICROCRYSTALLINE (Avicel PH-101): 
Synonyms: 
         Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; E460; 
Emcocel; Ethispheres ; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical Name : 
         Cellulose 
Functional Category : 
         Adsorbent; suspendin agent: tablet and capsule diluent; tablet disintegrant. 
Description: 
         Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially 
available in different particle sizes and moisture grades that have different properties and 
applications. 
Typical Properties: 
         Density (bulk)               :  0.32 g/cm for Avicel PH-101 
         Density (tapped)           :  0.45 g/cm for Avicel PH-101 
         Density (true)                :  1 .512–1.668 g/cm 
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         Melting point                :  Chars at 260–270°C. 
         Moisture content           : Typically less than 5% w/w. Microcrystalline cellulose  
                                                   is hygroscopic. 
         Particle size distribution: Typical mean particle size is 20–200 μm.  
Solubility:  
         Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, dilute 
acids, and most organic solvents. 
 
Stability and Storage Conditions: 
         Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
 
Safety: 
         Microcrystalline cellulose is widely used in oral pharmaceutical formulations and food 
products and is generally regarded as a relatively nontoxic and nonirritant 
material.Microcrystalline cellulose is not absorbed systemically following oral administration 
and thus has little toxic potential. 
Applications:  
         Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent 
in oral tablet and capsule formulations where it is used in  directcompression processes.  It is  
also has some lubricant and disintegrant properties that make it useful in tableting. 
Microcrystalline cellulose is also used in cosmetics and food products. 
 
Table 2: Uses of Microcrystalline cellulose. 
    Use Concentration (%) 
          Adsorbent 20–90 
          Antiadherent 5–20 
Capsule binder/diluents 20–90 
Tablet disintegrant 5–15 
Tablet binder/diluents 20–90 
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8. STARCH: 
Synonyms: 
         Amido; amidon; amilo; amylum; aytex p; cassava starch; fluftex W; melojel; paygel 55; 
pure-dent; tablet white. 
Description: 
         It occurs as an odorless and tasteless, fine, white-colored powder comprised of very small 
spherical or ovoid granules whose size and shape are characteristics for each botanical variety. 
Functional category: 
         Glidant; tablet and capsule diluents; tablet and capsule disintegrant; tablet binder. 
Solubility: 
         Practically insoluble in cold ethanol 95%  and cold water. 
PH:  
         5.5-6.5 
Density: 
         Bulk - 0.462 gm/cm3 
         Tapped- 0.658 gm/cm3 
Moisture content: 
         Hygroscopic and rapidly absorb atmospheric moisture. 
Stability and storage condition: 
         Dry, unheated starch is stable if protected from high humidity. When used as a diluent or 
disintegrant in solid dosage forms, starch is considered to be inert under normal storage 
conditions. 
Incompatibilities: 
         Nil 
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Safety: 
         It is widely used as an excipient in pharmaceutical formulations, particularly oral tablets. It 
is an edible food substance and is generally regarded as an essentially non-toxic and non-irritant 
material. 
Applications: 
         It is widely used as an excipient in oral dosage formulations where it is utilized as a binder 
diluent and disintegrant. In tablet formulations, freshly prepared starch paste is used at a 
concentration of 5-25% w/w in tablet granulations as a binder. It is one of the most commonly 
used tablet disintegrants at concentration of 3-15%w/w. 
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5.   EXPERIMENTAL INVESTIGATION 
5.1 CONSTRUCTION OF STANDARD CURVE OF LURASIDONE:71 
a) By UV spectroscopy method: 
            Lurasidone was estimated spectrophotometrically at 230nm and it obeys beer-lamberts 
law in the range of 5 – 25 mcg/ml. 
PROCEDURE: 
1) PREPARATION OF MCIl VAINES BUFFER: 
            2.58 gm of 0.1M Citric acid was taken in 1000 ml standard flask ( 0.1M = 21 gm of Citric 
acid in 1000 ml distilled water) and 1.2 gm of 0.2M sodium di hydrogen phosphate (0.2 M = 156 
gm of sodium di- hydrogen phosphate in 1000 ml distilled water) was taken and made up to 1000 
ml with distilled water. 
1. Preparation of  Standard curve of  Lurasidone pH 3.8 buffer:: 
a) Preparation of primary stock solution: 
            100 mg of lurasidone was taken in 100 ml standard flask. Then it was dissolved in 50 ml 
of methanol and made up to 100 ml volume with MCllVaines buffer to a concentration of 1000 
mcg/ml. 
b) Preparation of secondary stock solution: 
            From primary stock  solution 5 ml was taken in 100 ml standard flask and made up to 100 
ml volume with MCllVaines buffer to a concentration of 50 mcg/ml. 
c) Sample solution: 
            From secondary stock solution aliquots ranging from 1 to 5 ml were pipette out and 
diluted to 10 ml with  MCllVaines buffer to get the concentration of  5, 10, 15, 20, 25 mcg/ml the 
absorbance was measured at 230nm. 
2. Standard curve of Lurasidone HCL in pH 7.4 buffer: 
a) Preparation of primary stock solution: 
           100 mg of lurasidone was taken in 100 ml standard flask. Then it was made up to 100 ml 
with phosphate buffer pH 7.4 to a concentration of 1000 mcg / ml. 
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b) Preparation of secondary stock solution: 
                From primary stock  solution 5 ml was taken in 100 ml standard flask and made up to 
100 ml volume with phosphate buffer pH 7.4 to a concentration of 50 mcg/ml. 
 
c) Sample solution: 
            From secondary stock solution aliquots ranging from 1 to 6 ml were pipette out and 
diluted to 10 ml with phosphate buffer pH 7.4  to get the concentration of  5, 10, 15, 20, 25 and 30 
mcg/ml the absorbance was measured at 230nm. 
 A standard graph was plotted by keeping the known concentration on X axis and obtained 
absorbance on Y axis. 
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Table:3  Data  for  standard  curve  of  Lurasidone pH 3.8 buffer:: 
Concentration 
( mcg / ml ) 
Absorbance 
5 
 
0.191 
10 
 
0.375 
15 
 
0.561 
20 
 
0.750 
25 
 
0.942 
 
 
Fig:1 STANDARD CURVE OF LURASIDONE IN MCllVaines buffer: 
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Table:4  Data  for  standard  curve  of  Lurasidone pH 7.4 buffer:: 
Concentration 
( mcg / ml ) 
Absorbance 
5 
 
0.07 
10 
 
0.144 
15 
 
0.211 
20 
 
0.280 
25 
 
0.342 
30 
 
0.407 
 
Fig:2 STANDARD CURVE OF LURASIDONE IN pH 7.4 buffer:: 
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5.2 PREFORMULATION  STUDIES:72,73              
 Preformulation testing is an investigation of physical and chemical properties of drug 
substances alone and when combined with excipients. It is the first step in the rational 
development of  dosage forms. 
 The overall objective of  preformulation testing is to generate information useful to the 
formulation in developing stable and bioavailable dosage forms. 
 The use of preformulation parameters maximizes the changes in formulating an 
acceptable, safe, efficacious and stable product. 
 The drug (Lurasidone) in powder form and granules were subjected to the following 
physical test for 3 times and average values were noted. 
5.2.1  I.R SPECTRUM  FOR  LURASIDONE: 
            The IR spectrum of substances compared with that odtained concomitantly for the 
corresponding USP reference standard, provides perhaps the most conclusive evidence of the 
identity of the substance. Potassium bromide(KBr) method was carried out. Lurasidone and KBr 
were compressed under 15 tones pressure in a hydraulic press to form a transparent pellet. The 
pellet was scanned from 400 to 4000 cm-1 in IR spectrometer. 
5.2.2  DRUG- EXCIPIENTS COMPATIBILITY STUDIES: 
            About 500 mg of Lurasidone alone and mixtures cosisting of  Lurasidone with various 
excipients in 1 : 1 and 1 : 10 ratio in glass vial were taken and kept at various accelerated 
condition [25oC / 60% RH, 30oC / 75% RH, 40oC / 75% RH ] in stability chamber. It is carried 
for one month in open and closed glass vials. At the interval days of 1, 2, 3, 4, 5, 6, 14, 21 and 30 
days samples were withdrawn and physical characteristics like colour were recorded. Finally the 
mixtures with no colour change were selected for formulations. 
5.2.3  Determination of  Angle of Repose: 
            The pure drug and granules were subjected to angle of repose by funnel method. The 
frictional forces in a loose powder can be measured by the angle of repose, Ɵ. This is the 
maximum angle possible between the surface of a pile of powder and the horizontal plane. The 
angle of repose is calculated by  
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Ɵ = tan-1(h/r) 
              Ɵ = angle of repose 
              h  = height of the conical heap 
              r   = radius of the base of the heap 
5.2.4  Determination of  Bulk Density and Tapped Density: 
            An accurately weighed quantity of the powder (or) granules (W) were carefully poured 
into the graduated cylinder and the volume(V0) was measured. The  graduated cylinder was fixed 
in the density determination apparatus and tapped for 250 times and again subjected to 500 taps 
till the constant reading was obtained(Vf). The bulk and tap densities were calculated using the 
following formulae 
                          Bulk density       =       W/ V0     
                          Tapped density    =       W/ Vf                       
                 W    =  weight of the powder 
                  V0    =   initial volume 
                  Vf    =   final volume 
5.2.5  Determination of  Hausner  Ratio  and  Carr's  Index: 
            Hausner ratio and carr's index are the measures of interparticle friction and the potential 
powder arch (or)  bridge strength and stability respectively which have been widely used to 
estimate the flow properties of powder. 
            Hausner ratio and carr's index were calculated using the following equation:               
                                Hausner ratio        =      
ρ౪౗p
ρౘ౫ౢౡ                     
                        ρtap     =  tapped density of powder      
                        ρbulk     =  bulk density of 
                                  Carr's index        =        ρ౪౗p−ρౘ౫ౢౡρ౪౗p  x100                                          
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5.2.6    Loss on Drying: 
            It was done in Electronic Loss on Drying (LOD) apparatus (Sartorius, Germany).  
Weighed quantity of  1 gm sample was placed in the pan and the temperature was increased to 
105oC and the loss on drying in % was noted. 
5.3  FORMULATION OF BILAYER TABLETS 
 Preparation  of  immediate release layer of Lurasidone: 
            Lurasidone immediate release tablets were prepared by using direct compression method. 
Lurasidone, Croscarmellose sodium, Crospovidone powder, Sodium Lauryl Sulphate,  and  
starch were accurately weighed and passed through sieve number 40. All  the ingredients as 
shown in Table 4 were mixed  in a polybag. Magnesium stearate and  Talc were added after 
passing through sieve number 40  and mixed homogenously . 
Table:5  COMPOSITION OF IMMEDIATE RELEASE LAYER OF LURASIDONE: 
Ingredients Category F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
Lurasidone 
 
Active ingredient 12 12 12 
Croscarmellose 
sodium 
Superdisintegrant 10 - 10 
Crospovidone 
 
Superdisintegrant - 10 10 
Sodium lauryl 
sulphate 
Surfactant 4 4 4 
 
Magnesium stearate  
Lubricant 
1 1 1 
Talc Glidant 1 1 1 
 
Starch Diluent 172 172 162 
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    Preparation of  sustained  release  layer  of  Lurasidone: 
            Lurasidone sustained  release tablets were prepared by using direct compression method. 
Lurasidone, Hydroxy Propyl Methyl Cellulose (HPMC), and Micro Crystalline Cellulose were 
accurately weighed and passed through sieve number 40.mixed homogenously. All  the 
ingredients as shown in Table 5 were mixed in a polybag. Magnesium stearate and  Talc were 
added after passing through sieve number 40  and mixed homogenously .     
Table:6  COMPOSITION OF SUSTAINED RELEASE LAYER OF LURASIDONE : 
Ingredients       Category F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
F8 
(mg) 
F9 
(mg) 
Lurasidone 
 
Active 
ingredient 
28 28 28 28 28 28 28 28 28 
HPC 
 
Polymer 14 28 - - - - - - - 
HPMC(K4) 
 
Polymer - - 14 28 42 14 28 42 56 
HPMC(K100) 
 
Polymer - - - - - 14 28 42 56 
Magnesium 
stearate 
 
 
Lubricant 
4 4 4 4 4 4 4 4 4 
Talc 
 
Glidant 4 4 4 4 4 4 4 4 4 
MCC 
 
Diluent 400 386 400 386 372 386 358 330 302 
*each tablet weight is 450mg 
Tablet Compression: 
           The bilayer tablet compression was made using  10mm punch in a 16 station rotary tablet 
machine. In this, sustained release Lurasidone granules were introduced first into the die cavity 
and a slight pre-compression was made so that the layer was uniformly distributed after that 
immediate release Lurasidone granules were added and a  final compression was made.    
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5.4  EVALUATION OF TABLETS:74,75 
 a) Thickness and Diameter: 
           The thickness and diameter of the tablets were carried out using vernier caliper (Mitutoyo 
corps, Japan). Five tablets  were used for the above test from each batch and results were 
expressed in millimeter.    
b) Hardness Test: 
        Tablets required a certain amount of strength or hardness and resistance to friability to 
withstand mechanical shocks of handling in manufacture, handling and shipping. The hardness 
of tablets were measured by “Monsanto hardness tester”. Five tablets were used for hardness 
studies and results were expressed in Kg/cm2 
c)Weight variation Test: 
         Twenty tablets were selected at random individually weighed in a single pan   electronic 
balance  (Ax, shimadzu –corporation Japan  )  and the average weight was calculated. The 
uniformity  of weight was determinied according to I.P specification. As per I.P not more than 
two of individual weight would deviate from average weight by more than 5%  and non deviate 
more than twice that percentage. 
d)Friability Test: 
         The friability of the tablets were determined by Roche friabilator. In this apparatus, the 
tablets were subjected to the combined effect of abrasion and shock by utilizing a plastic 
chamber that revolves at 25 rpm, dropping the tablets at a distance of six inches with each 
revolution. Pre-weighed  20 tablets were placed in f riabilator, which is then operated for 100 
revolutions. The tablets were then dusted and  re-weighed. Conventional compressed tablets 
that lose less than 0.5 to 1.0%  of their weight are generally considered acceptable. 
        Friability =  Wୣ୧୥୦୲ l୭ୱୱWୣ୧୥୦୲ ୭୤ ୲ୟୠlୣ୲ୱ ୠୣ୤୭୰ୣ ୭୮ୣ୰ୟ୲୧୭୬ x100   
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d) In- vitro Dissolution Studies by U.V  Spectrophotometer : 
           In-vitro drug release studies of  Lurasidone was studied using dissolution apparatus USP 
XXI Rotating  basket method pH 1.2(0.1N HCl) buffer 900 ml was used at the dissolution 
medium. Tablet was placed in a basket and rotated at a speed of  50 rpm maintained at a 
temperature of  37 ± 0.5oC. One of the  sample was withdrawn at periodic time interval of 5, 10, 
15, 20, 25, 30mins and was made upto 10 ml  with 0.1N HCl buffer solution. One ml of  fresh          
dissolution medium  was replaced after each time of withdrawn of  sample. Followed by study in 
pH 7.4 phosphate buffer used in dissolution medium. the dissolution medium 1 ml were taken at 
an interval of 1, 2, 3, upto 12 hrs with replacement of equal volume of fresh dissolution medium. 
The sample was made upto 10 ml with buffer solution and its absorbance was measured at   230 
nm. The amount of drug was calculated using standard graph. 
 
f) Content  Uniformity  Test: 
Standard preparation: 
  Prepare a solution of USP Lurasidone in water having a known concentration of about 10 
mcg per ml. 
Sample preparation of Lurasidone: 
  One tablet was finely powdered and dissolved in 70 ml water shake by mechanical means 
for 15 mts, dilute with water to volume,  filter and discarding the first 20 ml of filtrate. Dilute 
10ml of   filtrate with water to 100ml and 10 ml of the resulting solution with water to 100 ml 
and measured the absorbance at 230 nm. 
5.5  STABILITY STUDIES:    
           As per in-vitro release formulation F8 was found to be desirable  than other  formulations. 
Hence it was chosen for stability studies. The tablets were chamber (Ostwald Mumbai), 60oC  in 
incubator.  At the interval of 1 month tablets were withdrawn and evaluated for physical 
properties like thickness, hardness,  diameter,  friability,  weight variation and content 
uniformity.  In- vitro drug release is also carried out. 
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5.6 DATA ANALYSIS: 
           To analyse the mechanism of release, the best formulation was subjected to some 
statistical tests. 
           Results of  the data were fitted into the following equation. 
 Zero order equation 
 First  order equation  
 Higuchi plot 
 Peppas plot   
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6.   RESULTS AND DISCUSSION 
           The present study was undertaken to formulate Lurasidone bilayer tablets. Sustained 
release dosage forms deliver the drug at a slow release rate over an extended period of time. The 
short biological half-life and  dosing frequency lesmore than one per day make the drug an ideal 
candidate for sustained release. 
           The tablets prepared in the  present study by direct compression method have advantages 
over those prepared by wet granulation in terms of time and energy consumption , thus making it 
possible to formulate tablets at a lower cost. Because of  their flexibility, hydrophilic polymer 
matrix systems are widely used in oral controlled drug delivery. 
           The study involved pre-formulation of  drugs and granules,  formulation and processing  
development along with evaluation of the tablets. 
6.1  PRE-FORMULATION  STUDY  OF  DRUG: 
 The Lurasidone was subjected to drug-excipients compatibility study with excipients like  
hydroxyl propyl methyl cellulose,  microcrystalline cellulose,   croscarmellose,  
crospovidone,  sodium lauryl sulphate,  magnesium stearate,  starch  and  talc.  The  
mixtures  shown  to have no color change. 
 The angle of repose for pure drug was very less and hence the poor flow of the pure drug 
was exhibited.  Also the carr's index of the pure drug was found to be high, confirming 
that the drug has poor flow properties and compressibility. 
 Good flow of powders / granules was improved by adding Excipients and is essential in 
tableting  because the  compressibility and flow properties of the drugs likely to influence 
the compression process in the preparation of tablets.  In view of this the formulation 
were prepared  by  direct compression technique to improve the flow as well as  
compressibility.           
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Table: 7 Pre-formulation study data of the pure drug 
      
                  
               
 
 
 
 
                
 
 
 
                
                
*Values mentioned are average of 3 determinations 
6.2   INFRA  RED  SPECTROSCOPIC  STUDIES: 
           By using  FTIR technique, Lurasidone and polymers like croscarmellose, crospovidone, 
hydroxyl propyl methyl cellulose, microcrystalline cellulose, sodium lauryl sulphate, starch, 
magnesium stearate, talc were identified by the frequency of obtained peaks. 
        The interpretation of the infra red spectrum of the drug and polymers are as follows 
 
 
 
S.N 
 
Parameters Values obtained 
1. 
 
Angle  of  repose 10.28     ±  0.002 
2. 
 
Loss  on  drying 0.408     ±  0.005 
3. 
 
Bulk  density (gm/ml) 0.3175   ±  0.006 
4. 
 
Tap  density (gm/ml) 0.4286   ±  0.003 
5. 
 
Hausner  ratio 1.3         ±  0.002 
6. 
 
Carr's  index 26.18     ±  0.561 
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Table:8  IR spectra of  pure  Lurasidone: 
Frequency ( cm-1) Groups Assigned 
1263.42 N-H stretching 
1681.96 C=C stretching 
2256.79 S-H stretching 
1761.07 C=O stretching 
3429.55 C-H stretching 
 
Table:9  IR spectra of  optimized  formulation: 
Frequency ( cm-1) Groups Assigned  
1026.16 N-H stretching 
1685.84 C=C stretching 
2254.86 S-H stretching 
1760.08 C=O stretching 
3377.47 C-H stretching 
 
IR  Report: 
        When FT IR Spectrum of  Lurasidone (pure drug), excipients and optimized formulation of  
Lurasidone  bilayer tablet   (F8) were compared, there were no major changes in the position of  
the spectrum. It indicates absence of  physical and chemical interaction among active component 
Lurasidone and excipients. So the bilayer tablet of  Lurasidone has no  interaction with added 
excipients. 
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6.3  EVALUATION  OF  POWER  BLEND: 
        The prepared granules of the formulations were evaluated for the parameters like bulk 
density, tap density, compressibility index, hausner ratio, angle of repose and loss on drying. 
 After granulation, angle of  repose was improved. 
 Hausner ratio was found to be 1.2 (or) less than 1.2 
 Carr's index was found to be in the range of 12-16 
 All these values indicated that the granules have good flow property and hence the 
granulation process has improved the flow property. 
 
Table:10  Physical Characteristics of immediate release powder blend 
Formulation 
Code 
Angle of 
repose(Ɵ) 
 
Loss on 
drying(%) 
Bulk 
density(g/ml) 
Tapped 
density(g/ml) 
Hausner ratio Carr's index 
F1 22.14±0.005 
 
1.70±0.846 0.5562±0.011 0.6896±0.002 1.168±0.003 11.62±0.531 
F2 23.11±0.002 
 
1.82±0.921 0.5742±0.012 0.6431±0.004 1.142±0.001 10.86±0.468 
F3 22.62±0.004 
 
1.97±0.682 0.5842±0.011 0.6426±0.005 1.153±0.004 12.44±0.379 
*Values mentioned are average of 3 determinations 
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Table:11  Physical Characteristics of sustained release powder blend 
Formulation 
Code 
Angle of 
repose(Ɵ) 
Loss on 
drying(%) 
Bulk 
density(g/ml) 
Tapped 
density(g/ml) 
Hausner 
ratio 
Carr's index 
F1 
 
25.56±0.54 1.18±0.987 0.358±0.010 0.412±0.002 1.19±0.005 15.42±0.213 
F2 
 
26.21±0.68 1.12±0.865 0.381±0.012 0.423±0.001 1.18±0.008 14.68±0.143 
F3 
 
25.42±0.42 1.15±0.963 0.390±0.014 0.415±0.004 1.12±0.009 16.21±0.572 
F4 
 
26.54±0.62 1.10±0.886 0.363±0.020 0.442±0.003 1.14±0.006 14.98±0.312 
F5 
 
25.89±0.31 1.17±0.928 0.371±0.015 0.428±0.001 1.13±0.005 15.56±0.124 
F6 
 
25.65±0.73 1.21±0.913 0.384±0.018 0.414±0.003 1.15±0.003 14.89±0.172 
F7 
 
25.32±0.81 1.13±0.829 0.375±0.019 0.426±0.005 1.2±0.002 16.12±0.711 
F8 
 
26.76±0.92 1.20±0.911 0.364±0.013 0.422±0.002 1.19±0.004 15.43±0.109 
F9 26.22±0.55 1.16±0.846 0.382±0.011 0.445±0.004 1.17±0.001 16.14±0.121 
*Values mentioned are average of 3 determinations 
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6.4   IN-VITRO   RELEASE  STUDIES: 
6.4.1  IN-VITRO   RELEASE  OF  IMMEDIATE  RELEASE  LAYER: 
        In formulation F1 formulation only croscarmellose sodium 10mg was used and release was 
found to be 14.58%.  Hence, to get more release it was decided to alter the formulation further. 
        In formulation F2 crospovidone 10mg was used and release was found to be 18.09%.  In F3  
formulation , combination of  croscarmellose 10mg and crospovidone 10mg  was used and 
release was found to be 29.66%  at 30 minutes. The percentage of drug release increased with 
combination of super disintegrants like croscarmellose sodium and crospovidone which may be 
due to its strong swelling property and highly porous structure of  crospovidone.  
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Table:12Dissolution  data  of  F1  Formulation: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig:3  Dissolution  profile  of  F1 Formulation: 
 
 
 
 
 
 
 
 
S.No Time (mins) Amount of drug 
release (mg) 
Cummulative % 
drug release 
1 
 
5 1.8 4.5 
2 
 
10 3.6 9.03 
3 
 
15 4.8 12.05 
4 
 
20 5.4 13.57 
5 
 
25 5.6 14.08 
6 
 
30 5.8 14.58 
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Table:13  Dissolution  data  of  F2  Formulation: 
S.No Time (mins) Amount of drug 
release (mg) 
Cummulative % 
drug release 
1 
 
5 2.3 5.75 
2 
 
10 4.7 11.78 
3 
 
15 5.8 14.57 
4 
 
20 6.1 15.33 
5 
 
25 6.8 17.08 
6 
 
30 7.2 18.09 
 
Fig:4  Dissolution  profile  of  F2 Formulation 
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Table:14 Dissolution  data  of  F3  Formulation: 
 
 
 
 
 
 
 
 
 
 
 
Fig:5  Dissolution  profile  of  F3 Formulation 
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S.No Time (mins) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 
 
5 8.4 21.0 
2 
 
10 9.0 22.62 
3 
 
15 9.7 24.38 
4 
 
20 10.4 26.13 
5 
 
25 11.2 28.15 
6 
 
30 11.8 29.66 
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6.4.2   IN-VITRO   RELEASE  OF  SUSTAINED  RELEASE  LAYER: 
          In F1, F2 formulations HPC in various concentration 14, 28 mg was used and release was 
found to be at the end of 24th hrs 85.05%,  86.85%  respectively. In F3, F4, F5 formulations 
HPMC (K4) in various concentration 14,28, 42 mg was used and release was found to be at the 
end of 24th  hrs 87.78%,  90.48% ,  92.3% respectively. 
          HPMC (K4M)  and  HPMC (K100) was selected for further formulation to increase the 
release of drug. 
          In F6, F7, F8 formulations HPMC (K4M) and HPMC (K100)   in various concentration 
14,28, 42 mg was used and release was found to be at the end of 24th hrs 94.1% ,  96.825%,  
99.53%  respectively. 
          In F9 formulation HPMC (K4M) and HPMC (K100) in concentration 56 mg was used and 
release was found to be at the end of 24th hrs 99.53%.  F8 formulation and F9 formulation in-vitro 
release profile have shown the same release at 24 hours. But F8 formulation shows the(99.53%) 
good release at minimum concentration of HPMC(84mg). So the formulation F8 was the 
optimized one.    
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Table:15 Dissolution  data  of  F1  Formulation: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 12.24 30.8 
2 2 13.24 33.27 
3 3 14.04 35.28 
4 4 14.99 37.67 
5 5 15.84 39.8 
6 6 17.34 43.57 
7 7 18.0 45.23 
8 8 19.4 48.75 
9 9 20.16 50.65 
10 10 21.01 52.80 
11 11 21.96 55.18 
12 12 23.44 58.91 
13 13 25.92 65.1 
14 14 27.11 68.13 
15 15 28.08 70.55 
16 16 28.80 72.39 
17 17 29.16 73.3 
18 18 29.98 75.35 
19 19 30.24 76.01 
20 20 30.89 77.64 
21 21 31.64 79.52 
22 22 32.76 82.33 
23 23 33.11 83.23 
24 24 33.84 85.05 
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Fig:6 Dissolution  profile  of  F1 Formulation: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
C
u
m
 
%
 
d
r
u
g
 
r
e
l
e
a
s
e
 
Time in hrs 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                                                              Page | 73  
 
Table:16  Dissolution  data  of  F2  Formulation: 
 
 
 
 
 
 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 12.24 30.80 
2 2 12.45 31.29 
3 3 12.96 32.58 
4 4 13.44 33.78 
5 5 14.04 35.28 
6 6 14.98 37.14 
7 7 15.84 39.80 
8 8 17.10 42.97 
9 9 18.01 45.23 
10 10 19.64 49.35 
11 11 20.16 50.65 
12 12 20.94 52.63 
13 13 21.96 55.18 
14 14 23.84 59.90 
15 15 25.92 65.10 
16 16 27.22 68.41 
17 17 28.08 70.55 
18 18 28.88 72.59 
19 19 29.16 73.30 
20 20 30.55 76.78 
21 21 31.76 79.82 
22 22 32.44 81.54 
23 23 33.24 83.55 
24 24 34.56 86.85 
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Fig:7 Dissolution  profile  of  F2 Formulation: 
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Table:17  Dissolution  data  of  F3  Formulation: 
 
 
 
 
 
 
 
 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.04 35.28 
2 2 15.02 37.74 
3 3 15.84 39.8 
4 4 17.83 44.79 
5 5 18.0 45.23 
6 6 19.68 49.45 
7 7 20.16 50.65 
8 8 21.01 52.80 
9 9 21.96 55.18 
10 10 23.88 60.01 
11 11 25.92 65.1 
12 12 27.44 68.96 
13 13 28.08 70.55 
14 14 29.45 74.01 
15 15 30.24 75.98 
16 16 31.46 79.07 
17 17 32.76 82.33 
18 18 33.10 83.20 
19 19 33.84 85.05 
20 20 34.04 85.57 
21 21 34.56 86.88 
22 22 34.64 87.08 
23 23 34.78 87.43 
24 24 34.92 87.78 
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Fig:8  Dissolution  profile  of  F3 Formulation: 
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Table:18  Dissolution  data  of  F4  Formulation: 
 
 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 15.84 39.60 
2 2 17.24 43.32 
3 3 18.01 45.23 
4 4 19.22 48.30 
5 5 20.16 50.65 
6 6 21.12 53.08 
7 7 21.96 55.18 
8 8 23.84 59.91 
9 9 25.92 65.10 
10 10 27.66 69.51 
11 11 28.08 70.55 
12 12 29.78 74.84 
13 13 30.24 75.98 
14 14 31.84 80.02 
15 15 32.76 82.33 
16 16 33.01 82.98 
17 17 33.84 85.05 
18 18 34.09 85.69 
19 19 34.56 86.88 
20 20 34.92 87.78 
21 21 35.12 88.28 
22 22 35.98 90.43 
23 23 36.0 90.49 
24 24 36.1 90.75 
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Fig:9 Dissolution  profile  of  F4 Formulation: 
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Table: 19  Dissolution  data  of  F5  Formulation: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 15.94 39.85 
2 2 18.64 46.82 
3 3 20.16 50.63 
4 4 21.10 53.03 
5 5 21.96 55.18 
6 6 23.75 59.68 
7 7 25.92 65.10 
8 8 27.44 68.96 
9 9 28.08 70.55 
10 10 29.21 73.41 
11 11 30.24 75.98 
12 12 31.55 79.29 
13 13 32.76 82.33 
14 14 33.14 83.31 
15 15 33.84 85.05 
16 16 34.09 85.69 
17 17 34.56 86.88 
18 18 34.71 87.25 
19 19 34.92 87.78 
20 20 35.24 88.58 
21 21 35.86 90.13 
22 22 36.01 90.48 
23 23 36.46 91.65 
24 24 36.72 92.30 
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Fig:10 Dissolution  profile  of  F5 Formulation: 
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Table: 20 Dissolution  data  of  F6  Formulation: 
 
 
 
 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.14 32.85 
2 2 14.81 37.22 
3 3 16.56 41.63 
4 4 19.08 47.93 
5 5 21.92 55.08 
6 6 25.07 62.98 
7 7 27.68 69.55 
8 8 29.24 73.49 
9 9 30.22 75.98 
10 10 31.35 78.79 
11 11 32.76 82.33 
12 12 33.29 83.68 
13 13 33.84 85.05 
14 14 34.22 86.02 
15 15 34.56 86.88 
16 16 34.79 87.45 
17 17 34.92 87.78 
18 18 35.56 89.38 
19 19 36.0 90.48 
20 20 36.4 91.5 
21 21 36.72 92.3 
22 22 36.99 92.99 
23 23 37.21 93.53 
24 24 37.44 94.1 
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Fig:11  Dissolution  profile  of  F6  Formulation: 
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Table: 21 Dissolution  data  of  F7  Formulation: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.51 33.78 
2 2 15.29 38.42 
3 3 17.35 43.56 
4 4 19.27 48.44 
5 5 21.13 53.11 
6 6 23.43 58.88 
7 7 25.30 63.58 
8 8 26.87 67.54 
9 9 28.57 71.82 
10 10 31.24 78.51 
11 11 32.44 81.54 
12 12 33.28 83.65 
13 13 33.79 84.93 
14 14 34.15 85.84 
15 15 34.92 87.77 
16 16 35.58 89.43 
17 17 36.0 90.49 
18 18 36.41 91.52 
19 19 36.72 92.3 
20 20 37.02 93.06 
21 21 37.80 95.0 
22 22 38.13 95.85 
23 23 38.32 96.32 
24 24 38.52 96.83 
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Fig:12 Dissolution  profile  of  F7  Formulation: 
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Table: 22 Dissolution data of F8 Formulation: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
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Fig:13  Dissolution  profile  of  F8  Formulation: 
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Table:23   Dissolution  data  of  F9  Formulation: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
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Fig:14  Dissolution  profile  of  F9  Formulation 
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6.5  EVALUATION  OF  TABLETS: 
   a)Thickness and Diameter: 
          The thickness and diameter were found in the range of 6.0 ± 0.024 to 6.5 ± 0.048 and 12.2  
±  0.047 to 12.9  ±  0.048 respectively.   
 
Table:24  Thickness  and  Diameter  data  of  the  Tablets: 
Formulation 
Code 
Thickness  (mm) ± S.D Diameter  (mm)  ± S.D 
F1 
 
6.3 ±0.024 12.5 ±0.048 
F2 
 
6.1 ±0.04 12.2 ±0.049 
F3 
 
6.0 ±0.048 12.3 ±0.04 
F4 
 
6.3 ±0.024 12.1 ±0.06 
F5 
 
6.5 ±0.048 12.2 ±0.024 
F6 
 
6.1 ±0.09 12.1 ±0.048 
F7 
 
6.0 ±0.024 12.93±0.047 
F8 
 
6.1 ±0.004 12.2 ±0.076 
F9 
 
6.1 ±0.048 12.2 ±0.042 
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b)Weight Variation,  Hardness  and  Friability: 
          Depending upon the ingredients of different formulations, the weight of  the tablet was 
fixed.  In each formulation, weight variation was within the I.P limit. Mostly, the variation was 
within ± 5%. The hardness of the different formulations ranged from 4-7 kg / cm2. All the 
formulations exhibited less than 1% friability. 
 
Table:25  Hardness,  weight variation  and  Friability  data  of  the  Tablets: 
Formulation 
Code 
Weight variation 
(mg)± S.D 
Hardness 
(Kg/cm2) ± S.D 
Friability (%) 
± S.D 
F1 
 
585±2.710 6.8±0.244 0.31±0.02 
F2 
 
600±1.962 6.4±0.251 0.26±0.04 
F3 
 
615±2.6 6.3±0.244 0.36±0.03 
F4 
 
595±3.71 6.7±0.244 0.36±0.037 
F5 
 
600±4.5 6.5±0.048 0.33±0.014 
F6 
 
610±3.92 6.3±0.447 0.30±0.009 
F7 
 
615±4.87 6.2±0.244 0.33±0.014 
F8 
 
625±4.62 6.1±0.316 0.33±0.009 
F9 
 
610±3.81 6.2±0.244 0.40±0.04 
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c) Content  Uniformity: 
          The results for content uniformity are presented in following table. The results were found 
to be within the limits (98 to 99.78%). It shows that the drug was uniformly distributed 
throughout the tablets. 
Table:26  Content  Uniformity  data  of the  Tablets: 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Formulation 
Code 
Content  Uniformity in 
Percentage  ± S.D 
F1 
 
99.18±0.24 
F2 
 
99.13±0.115 
F3 
 
98.67±0.08 
F4 
 
99.22±0.37 
F5 
 
98.56±0.43 
F6 
 
98.42±0.10 
F7 
 
99.15±0.22 
F8 
 
99.20±0.20 
F9 
 
98.89±0.115 
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6.6  STABILITY  STUDIES: 
          The optimized F8 formulation was subjected to accelerated stability conditions for 3 
months at 25oC /60% RH,  30oC/75%RH,  40oC/75% RH in a stability chamber (Osworld,  
Mumbai ).  At the interval of 1 month tablets were withdrawn and evaluated for various 
parameters like thickness,  diameter,  weight variation,  hardness  and  content  uniformity. The 
tablets did not show any variation in the tested parameters and the results are within the limits. 
 
Table:27 Comparison of  physical  parameters  for  optimized  formulation F8  and stability 
study data S1 batch: 
 
S.No 
Parameters F8 25oC / 60% RH 
At  the end of 
1st month 
At  the end of 
2nd month 
At the end 
of 3rd month 
1 
 
Thickness(mm) 6.1±0.048 6.1±0.047 6.2±0.038 6.3±0.038 
2 
 
Diameter(mm) 12.2±0.048 12.1±0.042 12.1±0.045 12.1±0.047 
3 
 
Hardness(kg/cm2) 6.2±0.244 6.2±0.045 6.2±0.221 6.2±0.115 
4 
 
Friability(%) 0.40±0.009 0.4±0.009 0.4±0.009 0.41±0.008 
5 
 
Weight Variation( 
mg) 
615±3.185 617±3.115 618±3.525 617±3.251 
6 
 
Content 
Uniformity 
99.20±0.115 99.10±0.11 99.72±0.112 99.7±0.11 
 
* F8:  Optimized formulation 
*S1:  Formulation F8  kept for stability study at temperature 25oC / 60% RH 
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Table:28 Comparison of  physical  parameters  for  optimized  formulation F8  and stability 
study data S1 batch: 
 
S.No 
Parameters F8 30oC / 75% RH 
At  the end of 
1st month 
At  the end of 
2nd month 
At the end 
of 3rd month 
1 
 
Thickness(mm) 6.1±0.048 6.1±0.047 6.1±0.048 6.1±0.038 
2 
 
Diameter(mm) 12.2±0.048 12.5±0.042 12.3±0.045 12.3±0.047 
3 
 
Hardness(kg/cm2) 6.2±0.244 6.1±0.045 6.1±0.221 6.0±0.115 
4 
 
Friability(%) 0.40±0.009 0.43±0.007 0.43±0.009 0.42±0.008 
5 
 
Weight Variation( 
mg) 
615±3.185 613±3.115 613±3.525 612±3.251 
6 
 
Content 
Uniformity 
99.20±0.115 99.09±0.11 99.08±0.112 99.0±0.11 
 
* F8:  Optimized formulation 
*S1:  Formulation F8  kept for stability study at temperature 30oC / 75% RH 
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Table:29 Comparison of  physical  parameters  for  optimized  formulation F8  and stability 
study data S1 batch: 
 
S.No 
Parameters F8 40oC / 75% RH 
At  the end of 
1st month 
At  the end of 
2nd month 
At the end 
of 3rd month 
1 
 
Thickness(mm) 6.1±0.048 6.1±0.047 6.1±0.048 6.1±0.038 
2 
 
Diameter(mm) 12.2±0.048 12.1±0.042 12.3±0.045 12.3±0.047 
3 
 
Hardness(kg/cm2) 6.2±0.244 6.3±0.045 6.2±0.221 6.0±0.115 
4 
 
Friability(%) 0.40±0.009 0.45±0.007 0.44±0.009 0.42±0.008 
5 
 
Weight Variation( 
mg) 
615±3.185 617±3.115 615±3.525 612±3.251 
6 
 
Content 
Uniformity 
99.20±0.115 99.15±0.11 99.09±0.112 99.0±0.11 
 
* F8:  Optimized formulation 
*S1:  Formulation F8  kept for stability study at temperature 40oC/75% RH 
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Table:30 Dissolution  data  of  F8  Formulation at 25oC / 60% RH after 1st month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
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Fig:15  Dissolution  profile  of  F8  Formulation at 25oC / 60% RH after 1st month:: 
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Table:31 Dissolution  data  of  F8  Formulation at 30oC / 75% RH after 1st month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
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Fig:16 Dissolution  profile  of  F8  Formulation at  40oC / 75% RH after 1st month: 
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Table:32 Dissolution  data  of  F8  Formulation at 40oC / 75% RH after 1st month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.88 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 42.34 
5 5 18.34 45.10 
6 6 19.41 47.76 
7 7 20.43 50.35 
8 8 21.44 52.88 
9 9 21.96 54.20 
10 10 22.85 56.42 
11 11 23.95 59.20 
12 12 25.36 63.42 
13 13 26.88 66.56 
14 14 28.64 70.98 
15 15 29.79 74.11 
16 16 31.25 77.52 
17 17 32.49 80.65 
18 18 33.77 82.87 
19 19 34.87 86.64 
20 20 36.02 89.54 
21 21 37.27 93.27 
22 22 37.96 95.01 
23 23 38.93 97.22 
24 24 39.77 99.97 
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Fig:17 Dissolution  profile  of  F8  Formulation at  40oC / 75% RH after 1st month:: 
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Table:33 Dissolution  data  of  F8  Formulation at 25oC / 60% RH after 2nd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
 
 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                                                              Page | 102  
 
Fig:18 Dissolution  profile  of  F8  Formulation at  25oC / 60% RH after 2nd month:: 
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Table:34 Dissolution  data  of  F8  Formulation at 30oC / 75% RH after 2nd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.51 33.78 
2 2 15.29 38.42 
3 3 17.35 43.56 
4 4 19.27 48.44 
5 5 21.13 53.11 
6 6 23.43 58.88 
7 7 25.30 63.58 
8 8 26.87 67.54 
9 9 28.57 71.82 
10 10 31.24 78.51 
11 11 32.44 81.54 
12 12 33.28 83.65 
13 13 33.79 84.93 
14 14 34.15 85.84 
15 15 34.92 87.77 
16 16 35.58 89.43 
17 17 36.0 90.49 
18 18 36.41 91.52 
19 19 36.72 92.3 
20 20 37.02 93.06 
21 21 37.80 95.0 
22 22 38.13 95.85 
23 23 38.32 96.32 
24 24 38.52 96.83 
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Fig:19 Dissolution  profile  of  F8  Formulation at  30oC / 75% RH after 2nd month: 
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Table:35 Dissolution  data  of  F8  Formulation at 40oC / 75% RH after 2nd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.51 33.78 
2 2 15.29 38.42 
3 3 17.35 43.56 
4 4 19.27 48.44 
5 5 21.13 53.11 
6 6 23.43 58.88 
7 7 25.30 63.58 
8 8 26.87 67.54 
9 9 28.57 71.82 
10 10 31.24 78.51 
11 11 32.44 81.54 
12 12 33.28 83.65 
13 13 33.79 84.93 
14 14 34.15 85.84 
15 15 34.92 87.77 
16 16 35.58 89.43 
17 17 36.0 90.49 
18 18 36.41 91.52 
19 19 36.72 92.3 
20 20 37.02 93.06 
21 21 37.80 95.0 
22 22 38.13 95.85 
23 23 38.32 96.32 
24 24 38.52 96.83 
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Fig:20 Dissolution  profile  of  F8  Formulation at  40oC / 75% RH after 2nd month: 
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Table:36 Dissolution  data  of  F8  Formulation at 25oC / 60% RH after 3rd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 14.28 34.70 
2 2 14.81 37.21 
3 3 16.03 40.28 
4 4 17.25 43.34 
5 5 18.34 46.10 
6 6 19.41 48.76 
7 7 20.43 51.35 
8 8 21.44 53.88 
9 9 21.96 55.20 
10 10 22.85 57.42 
11 11 23.95 60.20 
12 12 25.36 63.74 
13 13 26.88 67.54 
14 14 28.64 71.98 
15 15 29.79 74.86 
16 16 31.25 78.53 
17 17 32.49 81.65 
18 18 33.77 84.87 
19 19 34.87 87.64 
20 20 36.02 90.54 
21 21 37.27 93.67 
22 22 37.96 95.42 
23 23 38.93 97.86 
24 24 39.77 99.97 
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Fig:21  Dissolution  profile  of  F8  Formulation at 25oC / 60% RH after 3rd month:: 
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Table:37 Dissolution  data  of  F8  Formulation at 30oC / 75% RH after 3rd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.51 33.78 
2 2 15.29 38.42 
3 3 17.35 43.56 
4 4 19.27 48.44 
5 5 21.13 53.11 
6 6 23.43 58.88 
7 7 25.30 63.58 
8 8 26.87 67.54 
9 9 28.57 71.82 
10 10 31.24 78.51 
11 11 32.44 81.54 
12 12 33.28 83.65 
13 13 33.79 84.93 
14 14 34.15 85.84 
15 15 34.92 87.77 
16 16 35.58 89.43 
17 17 36.0 90.49 
18 18 36.41 91.52 
19 19 36.72 92.3 
20 20 37.02 93.06 
21 21 37.80 95.0 
22 22 38.13 95.85 
23 23 38.32 96.32 
24 24 38.52 96.83 
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Fig:22 Dissolution  profile  of  F8  Formulation at  30oC / 75% RH after 3rd month: 
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Table:38 Dissolution  data  of  F8  Formulation at 40oC / 75% RH after 3rd month: 
S.No Time (hrs) Amount of 
drug release (mg) 
Cummulative % 
drug release 
1 1 13.51 33.78 
2 2 15.29 38.42 
3 3 17.35 43.56 
4 4 19.27 48.44 
5 5 21.13 53.11 
6 6 23.43 58.88 
7 7 25.30 63.58 
8 8 26.87 67.54 
9 9 28.57 71.82 
10 10 29.24 73.50 
11 11 30.43 76.48 
12 12 31.24 78.51 
13 13 32.44 81.54 
14 14 33.28 83.65 
15 15 33.79 84.93 
16 16 34.15 85.84 
17 17 34.92 87.77 
18 18 35.58 89.43 
19 19 36.0 90.49 
20 20 36.41 91.52 
21 21 36.72 92.3 
22 22 37.02 93.06 
23 24 37.80 95.0 
24 24 38.13 95.85 
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Fig:23 Dissolution  profile  of  F8  Formulation at  40oC / 75% RH after 3rd month: 
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6.7  PHENOMENON  OF  DRUG  RELEASE: 
          The formulations were subjected to graphical treatments to access the kinetics of drug 
release. 
          Release was approaching Zero order. 
Zero  order  Equation: 
          The results data was fitted into the Zero order equation. 
              Q  =  Kot 
              Q  =  The amount of drug release at time t 
              Ko  =  Release rate 
First  order  Equation: 
          The results data was fitted into the First order equation. 
              Log C = Log Co – kt / 2.303 
              Co       = initial concentration of drug 
              K       = first order constant 
              t         = time 
Higuchi  Plot: 
          The graph was plotted between cumulative % release and square root of time. The 
regression value of  F8  was 0.931. This indicates,  that diffusion is one of  the mechanism of  
drug release. 
Peppas  Plot: 
          The graph was plotted between log cumulative % release and log time. The slope (n) value 
of  F8 was 0.978. This indicates, that fickian diffusion mechanism of  drug release. 
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Fig:14  Zero order kinetics Treatment of optimized formulation F8 
 
 
 
Fig: 15  First order kinetics Treatment of optimized formulation F8 
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Fig: 16 Higuchi’s  Treatment of optimized formulation F8 
 
 
 
Fig: 17  Peppa’s plot Treatment of optimized formulation F8 
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7.  CONCLUSION 
          The  Bilayer  tablets  of  Lurasidone  were prepared by direct compression. F8 is 
considered to be the optimized formulation with the desired drug release. The polymers which 
have been used in the best formulation (F8)  are Croscarmellose, Crospovidone, HPMC 
[K4,K100], MCC, starch, sodium lauryl sulphate, Magnesium stearate and Talc. 
          The granules were evaluated for angle of  repose, bulk density, tapped density, hausner’s 
ratio, carr’s index and moisture content. The tablets were subjected to weight variation, 
thickness, hardness, friability, drug content and in-vitro release studies. 
          The results of  FTIR analysis of  pure drug, drug-excipients mixtures and tablet 
formulations showed that there was no physical and chemical interaction of  drug with the other 
excipients. 
          The stability studies of  optimized formulation F8  at 25oC/60% RH, 30oC/75% RH, 
40oC/75% RH for 3 months did not show any variation in the tested parameters and release also. 
          The phenomenon of  drug release shown that the release of  optimized formulation  F8  is 
controlled by Fickian diffusion. 
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